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CHAPTER 1 
GENERAL INTRODUCTION  
Statement of the problem 
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent 
of Johne’s disease in cattle and wild ruminants.  Johne’s disease is a chronic progressive 
fatal disease that presents difficulty in establishing an accurate diagnosis, especially in 
the early stages of disease.  The lack of accurate and early detection of Johne’s disease 
has hindered efforts to control or eliminate the disease from US dairy herds.  
Unfortunately, according to the most recent NAHMS survey (NAHMS, 2008), Johne’s 
disease prevalence has increased to over 90% in US dairy herds.  The use of cell-
mediated immune (CMI) response testing methods is the best option for early disease 
detection.  Test methods measuring CMI responses in the early stages of disease have 
been shown to provide better detection rates when compared to serological based test 
methods (Gwozdz, 2000).  The use of MAP purified protein derivative (PPD) in either 
the intradermal skin test or gamma-interferon (IFN-γ) test provide an indicator of the 
early cell-mediated immune response to MAP infection.   
The lack of consistent PPD production methods leads to variances in potency 
between production lots which contributes to problems in specificity during skin test 
procedures as well as in the IFN-γ assay.  Until recently, research related to the 
characterization of MAP PPD protein components had been lacking.  In 2005, the United 
States Animal Health Association Committee on Johne’s Disease addressed this concern 
with the approval of a resolution tasking the National Veterinary Services Laboratories 
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(NVSL) of the United States Department of Agriculture (USDA) with the development of 
a systematic protocol for the production and characterization of a consistent MAP PPD.   
This dissertation research project is directed toward addressing this need through 
the improvement of the current MAP PPD production process, and to characterize current 
MAP PPD production lots, in an effort to arrive at a well characterized and consistent 
PPD that can be reliably used in both intradermal skin test procedures and the IFN-γ 
assay for early detection of MAP infections. 
 
Development of an improved MAP PPD production process 
MAP PPD is a crudely prepared protein suspension that is precipitated by 
trichloroacetic acid from autoclaved MAP culture supernatants.  Studies have shown that 
Mycobacterium bovis and Mycobacterium avium infected animals can cross react with 
MAP PPD (Jungersen et al., 2002; McDonald et al., 1999).  These non-specific reactions 
lend to diminished support for PPD use in skin testing animals, or for use in the IFN-γ 
assay.  PPD production methods have remained the same since the early 1940s and 
production improvements should be re-examined in light of newer technologies.  
Outdated production processes require extensive incubation times for sufficient culture 
growth.  The lack of formal production protocols detailing incubation times and specific 
MAP strain for use contributes to inconsistencies between PPD suspensions (Wynne et 
al., 2012).  Previous work was successfully conducted at the USDA to produce a 
reference MAP PPD by using current production methods and demonstrated acceptable 
biological activity in MAP sensitized guinea pigs (Steadham et al., 2002).  Improvements 
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in production methods and the consistent protein composition of MAP PPDs are 
imperative to allow for improved and consistent in-vivo and in-vitro testing procedures. 
 
Characterization of MAP PPD composition 
Until recently, interest in defining the components of MAP PPD was not a point 
of emphasis.  Two questions have followed PPD production over the years.  The first is 
the mycobacterial strain used for production processes.  Originally, an isolate incorrectly 
referenced as MAP Strain 18 was used for MAP PPD production and was later 
characterized to be Mycobacterium avium subsp. avium and not a true MAP isolate 
(Chiodini, 1990; Merkal, 1979).  This culture confirmation work led to a proposal to 
discontinue referencing Strain 18 as MAP and to discontinue its use in MAP PPD 
production processes (Chiodini, 1993).    MAP ATCC 19698, a confirmed MAP cattle 
isolate, was proposed as the MAP neotype strain (Merkal, 1979).  MAP ATCC 19698 has 
been used at the NVSL since the late 1990s for MAP PPD production processes. 
Genetic analysis of mycobacterial culture strains used for PPD production has 
continued and revealed considerable genomic differences exist between isolates used for 
reagent production (Semret et al., 2006a).  The acceptance of MAP ATCC 19698 as a 
production strain in many laboratories accompanied by further genetic analysis has 
allowed for consistent use of a specific well-characterized strain for PPD production. 
A second question complicating the use of mycobacterial PPDs in general is the 
lack of information related to the protein composition of preparations.  This process is 
complicated due to the breakdown of protein components due to autoclaving during the 
PPD production process.  Proteomic analysis of mycobacterial PPD suspensions has been 
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examined in recent years (Cho et al., 2012; Prasad et al., 2013; Wynne et al., 2012).  The 
greatest number of proteins identified in any of these studies was 265 from a 
Mycobacterium tuberculosis PPD (Prasad et al., 2013) and 134 proteins in a MAP PPD 
(Wynne et al., 2012)  Identification of all protein components in PPD could lead to an 
increased ability to screen for immunologically significant components contributing to 
improved and more consistent PPD preparations.   
    
Evaluation of MAP PPD 
 At the NVSL, PPD preparations are evaluated for sterility, protein concentration, 
phenol content, and potency prior to release for use in the field.  There are no specific 
protein composition evaluations currently conducted by various laboratories producing 
PPD to ensure consistency of PPD composition between production lots.  This 
inconsistency can lead to differences in potency and varying specificity levels.  Induction 
of IFN-γ responses can vary significantly depending upon the PPD preparation used (de 
Lisle et al., 1980; Robbe-Austerman et al., 2006a; Robbe-Austerman et al., 2006d).   
These differences can lead to inconsistency when utilizing the intradermal skin test and 
IFN-γ assay.  The addition of methodologies allowing for identification and measurement 
of specific protein components may contribute to increased consistency between 
production batches.  However, this type of approach can only be implemented with 
improvements to production methods allowing for production of a well-characterized 
PPD.   
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Evaluation of MAP recombinant proteins 
While PPD proteins have been identified through proteomic analysis, there is still 
a major knowledge gap regarding which of the 4300-plus proteins that may be useful in 
producing an immunologically potent PPD.  Interest in the identified proteins has 
primarily been focused upon their use in antibody based serological assays.  However, in 
the early stages of infection the immune response promotes a T-helper type 1 (Th1) 
polarization of the immune response which is accompanied by MAP-specific IFN-γ 
production (Stabel, 2006; Stabel and Whitlock, 2001).  Evaluation of MAP recombinant 
proteins that will provide specific and potent IFN-γ stimulation could provide for 
improved diagnostics for earlier detection of MAP infected cattle.   
Evaluation of recombinant proteins, emphasizing usefulness in cell-mediated 
immune response detection protocols, would also include guinea pig potency testing as 
an in-vivo model in addition to use as mitogens in an IFN-γ assay as an in-vitro model.  
An understanding of possible differences of biological activity in an in-vivo versus in-
vitro model will be important to determine possible recombinant protein selection that 
can provide for use in both the field and laboratory settings. 
 
Research objectives 
 The overall goal of this research was to provide a foundation for production of a 
more consistent, potent, and well-characterized MAP PPD that can be used for testing of 
CMI responses to MAP infection.  The first step to address this objective was to evaluate 
the current production method and subsequently utilize this information to investigate 
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possible adaptations which would allow for development of an improved and 
reproducible production process (Chapter 3).  The next step was to evaluate the potency 
of the various MAP PPD suspensions to determine if varying production methods may 
have an effect upon biological activity of the product and to characterize the specific 
protein composition of PPD (Chapter 4).  A final step in the research was to evaluate and 
identify specific recombinant proteins as candidates for use in skin test procedures and as 
mitogens for in-vitro gamma-interferon (IFN-γ) testing (Chapter 4).  Results of this work 
identified a number of proteins that are reactive in skin testing using sensitized guinea 
pigs and as mitogens in an IFN-γ assay.  These results can contribute to improvements 
toward a well-defined and consistent reagent for use in in-vivo and in-vitro test 
procedures.  
 
Dissertation organization 
The dissertation is composed of a general introduction, a literature review chapter, 
and two additional individual chapters containing research data in a format in which they 
will be submitted for publication.  Chapter 2 is the literature review and has the citations 
listed at the end of the chapter.  Chapter 3 is entitled “Development of an improved 
production method for Mycobacterium avium subsp. paratuberculosis purified protein 
derivative” and provides research findings involving development of an improved PPD 
production method.  Chapter 4 is entitled “Composition and potency characterization of 
Mycobacterium avium subsp. paratuberculosis purified protein derivatives and protein 
components” and provides research findings involving potency testing and proteomic 
analysis of PPD preparations.  Further information is provided regarding results using 
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recombinant proteins, identified from mass spectrometry analysis of PPD, in the guinea 
pig potency test and as antigens in the IFN-γ test.  Chapter 5 is a general conclusions 
section that summarizes the research presented in the dissertation and provides 
suggestions on future research. 
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CHAPTER 2:  LITERATURE REVIEW 
 
Johne’s disease discovery 
The discovery of Johne’s disease was initially described by Johne and Frothingham in 1895 
and was thought be bovine tuberculosis (Johne V.A., 1895).  Description of the clinical signs that 
include emaciation, inflammation, and a thickened intestine resemble what are now the known 
indicators of clinical Johne’s disease.  Later in 1906, the disease was recognized as being distinct 
from bovine tuberculosis and the disease name was changed to Johne’s disease or 
pseudotuberculosis (Bang, 1906).  In the years following these early findings, the acid-fast bacilli 
attributed to these infections were isolated, characterized, and subsequently used to reproduce the 
disease in calves and laboratory animals (Marek, 1910; Twort, 1914; Twort, 1912).  A report in 
the early 1900s indicated that the use of M. avium tuberculin resulted in a positive skin test 
response in MAP infected cattle, whereas Mycobacterium bovis (M. bovis) tuberculin did not 
elicit a response (Bang, 1909).  The ability to isolate and grow the organism as well as the 
finding that M. avium tuberculin elicited a skin test response were important steps for testing the 
presence of Johne’s disease.  The organism was originally known as Mycobacterium 
paratuberculosis and has been associated with Johne’s disease since 1923.  (Bergey, 1923). 
Johne’s disease is a chronic and progressive wasting disease caused by Mycobacterium 
avium subsp. paratuberculosis (MAP).  Infection is normally established in young, nursing 
animals through the fecal-oral transmission route.  A variety of animals are susceptible to 
infection including domestic and wild hoofstock (Council, 2003).    
The overall susceptibility to infection appears to wane as an animal ages.  Studies in dairy 
cattle have supported this theory even though the specific biological aspect of this susceptibility 
is not precisely understood (Larsen et al., 1975).  If as adult cattle there is exposure to large or 
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reoccurring doses of MAP, infection may occur in spite of reduced susceptibility (Payne, 1961; 
Rankin, 1961, 1962). 
In the United States, the prevalence of MAP infection in dairy cattle has continued to 
increase.  Two surveys conducted by the USDA have indicated there is increased knowledge 
among producers about Johne’s disease; yet, the incidence of infected animals continues to 
increase.  In the 2007 survey, results indicated that cattle in 68 percent of U.S. dairy operations 
were infected with MAP (NAHMS, 2008). 
Because of the slow progression of Johne’s disease, the ability to detect disease in herds 
can be problematic.  Four distinct stages of disease progression have been described as silent 
infection, subclinical disease, clinical disease, and advanced clinical disease (Whitlock and 
Buergelt, 1996).  As the name implies, the silent infection stage shows no obvious disease signs 
and this early stage would usually be found in young animals.  Subclinical disease would again 
offer no obvious signs of disease, but tests for cell mediated immune responses may detect 
animals at this stage of infection.  At this stage, identification of infected animals may 
infrequently be detected by isolation of MAP from fecal cultures.  The last two stages of disease 
often develop after one or more years following infection with MAP.  Typical signs are weight 
loss, diarrhea, milk production decreases, lethargy, and increased weakness.  Difficulties can be 
encountered during clinical disease because of challenges in obtaining an accurate diagnosis of 
Johne’s disease (Whittington and Sergeant, 2001).         
The economic impact of Johne’s disease is estimated to reach into the millions of dollars 
annually.  In New England, there was an estimated loss of $15.4 million dollars annually 
(Chiodini et al., 1984) while in Pennsylvania annual losses were estimated near $5.4 million 
dollars (Whitlock, 1985).  A USDA study estimated a loss of approximately $200 per cow each 
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year with an overall economic loss of between $200 million to $250 million dollars annually to 
the U.S. dairy industry (Garry, 1999).  The economic toll of this disease on the dairy industry is 
the primary motivation for efforts at disease control. 
 
Johnin and PPD development – growth and production 
Shortly following the successful isolation and characterization of Mycobacterium 
paratuberculosis (MP) an antigen referenced as Johnin was successfully produced from growth 
of MP on a beef-broth based liquid medium (M'Fadyean J., 1916).  Organisms in the growth 
media were filtered out of the suspension, and the media was then heat concentrated.  This 
original work records testing conducted on experimentally and naturally infected cattle, goats, 
and sheep over a five-year period.  Testing was conducted utilizing an intradermal route, as well 
as intravenous and conjunctival routes.  A majority of animals infected with MP did respond to 
Johnin as evidenced by a thickening of the skin at the injection site, but the reactions were 
weaker than those observed in M. bovis infected animals tested with M. bovis tuberculin and 
when M. avium tuberculin was used to test M. avium infected cattle.  The report also indicates 
that the Johnin-elicited responses in both M. bovis and M. avium infected animals gave concern 
related to possible cross-reactions to animals infected with other mycobacteria.  While there was 
disappointment in the sensitivity and specificity of this initial Johnin preparation, it was the first 
step in production of such antigen.   
Further work indicated no differences in detection of infected animals with the use of either 
Johnin or avian tuberculin, though there were indications that differences existed between 
production batches (Hagan, 1928).  Advances in making Johnin with organisms grown on 
synthetic media containing dead M. phlei organisms as a supplement occurred in 1932 
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(Broerman, 1932).  Continued production trial modifications to media formulations provided 
greater support for the use of synthetic media due to the elimination of reactive animal proteins 
from the media (Dunkin, 1933; Watson, 1935).  The removal of M. phlei from culture media in 
1933 indicated that Johnin could still be produced with a satisfactory potency using this media 
recipe (Dunkin, 1933).   These improvements in Johnin production processes, including using 
synthetic media for growth, later led to successful field use of Johnin produced in this manner 
(Minnett, 1935; Watson, 1935).  Investigations into better standardization and use of guinea pigs 
and other laboratory animals to test potency occurred in subsequent years (Glover, 1941a, b; 
Johnson, 1944; Johnson, 1942; Konst, 1943).  Potency, or measurement of biological activity, 
was determined by the skin test responses of the various Johnin products in the sensitized guinea 
pigs and allowed researchers improved information for determining optimal concentration of 
Johnin.  Johnson also demonstrated the use of sensitized cattle for potency testing of Johnin 
products (Johnson, 1944).  An additional study involved cattle sensitized against various 
mycobacterial species and compared the performance of Johnin versus PPDs produced from M. 
avium, M. bovis, M. tuberculosis var. hominus, and M. phlei (Johnson et al., 1949). 
During the early developmental stages of Johnin production heat concentrating culture 
filtrates through an evaporative process was the standard production method. This procedure 
consisted of exposing liquid culture flask suspensions to flowing steam or by placement within a 
water bath for a period of a few hours allowing for reduction of culture volume through a heat 
evaporation process.  The remaining contents were then filtered to remove clumps of 
mycobacteria, resulting in a culture filtrate referred to as Johnin.  In 1943 McIntosh and Konst 
demonstrated the successful production of a purified protein derivative (PPD) by adding a 
protein precipitation step to the process (McIntosh and Konst, 1943).  After obtaining the final 
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culture filtrate one volume of trichloroacetic acid (TCA) was added to every nine parts of culture 
filtrate and allowed to stand overnight.  The supernatant was then removed and the protein 
precipitate washed with 1% TCA, centrifuged, and the supernatant discarded.  The precipitate 
was then washed multiple times with anhydrous acetone followed by multiple washes with ether.  
The PPD was then dried and the resulting powder stored for later reconstitution and use.   This 
was an important advancement as purified protein derivatives were standardized based on protein 
concentration.  They were shown to be superior to previous heat concentrated culture filtrates 
(Larsen et al., 1955). 
During this same period of time, the Bureau of Animal Industry had a strong interest in 
further evaluation of products for the diagnosis of Johne’s disease, and a statistician derived and 
published two methods which could be used for comparing allergens, now known as PPD, in 
cattle (Wadley, 1948, 1949).  These evaluation methods were used in many of the Johnin studies 
that were conducted by Larsen and Johnson in the mid and late 1940s.    
Improved production methods utilizing more highly purified preparations and comparing 
the specificities and potency of such products occurred in the early 1950s (Annau, 1959; 
Baisden, 1950; Baisden, 1952).  Fractionation procedures with the use of alcohol, phenol, and 
acid allowed greater purification of proteins and showed overall promising advancements to 
existing production methods (Jones, 1953a, b, c).  These fractionation studies involved further 
product concentration utilizing phenol followed by an additional fractionation step using alcohol.  
This additional alcohol step was added to remove the PPD active material from the phenol 
extract product.  This additional alcohol fractionation was thought to result in a PPD with 
increased specificity. 
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The addition of one part of 40% TCA to nine parts of culture filtrate (vol:vol) is still used 
in the current MAP PPD production method; but the use of the phenol and alcohol extraction 
processes is no longer included.  Following this work in the 1950’s there was a period of about 
50 years where little new information was published on PPD production processes. 
While the production method was now established, a more defined starting culture was 
needed.  During the advances in Johnin and PPD production there still existed concerns over the 
specific cultures used in these procedures.  Beach and Hastings originally expressed concern that 
in less advanced cases of Johne’s disease the use of an avian tuberculin resulted in no positive 
identification of infected animals.  This work indicated the importance of selection of the true 
causative agent as well as media formulations when producing Johnin products (Beach and 
Hastings, 1922).  A laboratory-adapted M. avium strain which was subsequently known as 
United States Department of Agriculture strain 18 had been commonly used for PPD production 
and was placed within the American Type Culture Collection (ATCC) (Merkal, 1979).  Merkal 
later recognized culture Strain 18 growth requirement differences from other confirmed MP 
isolates.  It was demonstrated that Strain 18 grew relatively rapidly without the addition of 
mycobactin, but true MP isolates required this iron chelating agent for growth and also had 
longer incubation times for satisfactory growth.  Accompanying the culture growth 
characteristics, Strain 18 was found to be nonpathogenic for calves.  In 1968 Merkal requested 
that ATCC remove Strain 18, because it was no longer believed to be MP, and replaced it with a 
field isolate that was ultimately identified as ATCC 19698 (Merkal, 1979). Continued research 
related to Strain 18 confirmed it was an M. avium isolate (Chiodini, 1990; Collins et al., 1990; 
Kunze et al., 1992).  However, reference to Strain 18 continued in the literature during this time 
and in 1993 it was recommended that journal publications disallow reference of Strain 18 as a 
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MAP isolate and to ensure it is correctly identified as an M. avium isolate (Chiodini, 1993).  
During this period of time advancements were ongoing to improve the characterization and 
classification of MP.  A numerical taxonomy analysis of 38 MP strains was conducted using 22 
various tests and from this work it was determined that MP should be reclassified as MAP 
(Thorel et al., 1990).  The refined classification divided subspecies of the various bacterial 
strains corresponding to pathogenicity and host range in addition to the molecular evaluations 
conducted. 
In 2002, a reference MAP PPD was produced and results from potency testing indicated 
this particular PPD was comparable in regards to potency to a previous Johnin product made 
from M. avium strain 18 and could serve as a MAP PPD reference (Steadham et al., 2002).  This 
was an important step in having a reference MAP PPD available since previous work showed 
that PPD preparations produced from M. avium Strain 18 led to confusion and concerns that this 
strain was not representative of MAP isolates from cattle.  
 
Intradermal skin testing for Johne’s disease 
In the US the first use of a Johnin product occurred in Wisconsin on a known infected dairy 
herd.  The test utilized an intravenous administration for a majority of the cattle, and five 
additional animals were injected subcutaneously (Hastings EG, 1918).  An intravenous 
inoculation route of Johnin for cattle testing was subsequently reported involving two other herds 
(Miller, 1928; Turner, 1929).   
Even though the intravenous inoculation route was the accepted method for cattle testing, 
work was being conducted on intradermal injections for evaluation of a delayed type 
hypersensitivity (DTH) response.  Dunkin conducted a study involving double intradermal 
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injections approximately 24-48 hours apart followed by evaluation of the subsequent DTH 
responses on the skin at the injection site (Dunkin, 1928).  Non-specific skin reactions were 
observed in animals considered to be uninfected and Dunkin’s conclusion was that such 
responses could be distinguished from exposed animals based upon the size and diffuse nature of 
skin swellings (Dunkin, 1928).  A 1929 report also using a double intradermal skin test provided 
additional information related to skin swelling characteristics, but emphasized the diffuse nature 
and temperature of the swellings rather than swelling size (Isherwood, 1929).  However, swelling 
size would ultimately become the metric used to determine exposure to MAP. 
A double intradermic skin test study utilizing multiple tests on animals in a herd over a 3-4 
month time period was conducted using both Johnin, M. bovis and M. avium tuberculin in 
animals (Minnett, 1935).  An important observation from this study was that the researchers 
recognized variability in skin responses over a period of time.  Another report utilizing the 
double intradermal skin test concluded that use of this testing method was satisfactory for 
detecting animals that may be in the preclinical stages of disease (McConnell, 1935).  These two 
reports involved herds with known positive animals and varying degrees of skin test responses.  
An initial indication of the specificity of Johnin was reported involving the use of Johnin in a 
herd with no history of Johne’s disease.  The study was conducted over a three-year period 
(Johnson and Pratt, 1944).  Initial testing of the herd resulted in seven skin test positive animals 
and over the study period these specific animals were tested approximately every three months.  
No clinical signs had developed or were detected in these animals over the seven years it had 
taken to build the herd.  This study also tracked milk production with no decreased milk 
production volumes observed.  It was concluded, that although animals may be infected or 
simply exposed, the level of infection was insufficient to produce clinical disease, yet was 
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detectable by skin testing.  Another possibility was that the animals may be infected by other 
mycobacterial agents that shared antigenic determinants and cross-reacted to Johnin.        
Transition from use of the caudal fold area to the neck region resulted from studies 
conducted to evaluate intradermal injection site locations on cattle (Baisden, 1951; Larsen, 1950; 
Sikes and Groth, 1950).  Data from these studies revealed that there was a significant difference 
between skin test responses in the neck region compared to regions such as the back, side, and 
caudal fold region.  Sensitivity of the neck region was two to three times greater than other test 
regions on cattle.  In support of the use of a cell-mediated immune response test it was shown 
that transfer of sera from MAP sensitized guinea pigs into MAP negative guinea pigs did not 
elicit a positive skin test response (Howell, 1957).  An accompanying finding by Howell in this 
study was that if cells from the peritoneal cavity of MAP sensitized animals were transferred into 
MAP negative guinea pigs that a positive skin test resulted.  This finding confirmed the DTH 
response observed in cattle was the result of a cellular immune response.  Since these early 
studies the use of the intradermal skin test has remained a constant over the years when 
conducting field trials on dairy cattle. 
 
Difficulties associated with Johne’s skin testing 
Studies addressing concerns of anergy due to repeated testing were conducted around 1950.  
Larsen reported a 55% response rate one week after initial testing of MAP-sensitized cattle 
followed by 87% responding four weeks after initial testing (Larsen, 1949).  A follow-up study 
by Sikes using both naturally and artificially infected cattle indicated that a loss of skin test 
responsiveness was more likely to be observed in naturally infected animals than the 
experimentally infected animals (Sikes et al., 1951).   Further elucidation of possible anergy 
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continued in 1953 when Sikes used naturally infected cattle and nine different intradermal 
injection sites over a 20-week period (Sikes, 1953).  Intradermal testing was conducted at the 
nine various injection sites at 14, 16, 18, and 20 weeks after the initial intradermal skin test.  
Findings in this study were similar to the previous studies in that animals were more likely to 
have decreased response rates at earlier repeated test time periods following the initial skin test.  
This study also found there were issues related to local injection site desensitization.  Sikes 
concluded that if repeated intradermal injections were to be conducted at the same site that a 
period of 20 weeks should be allowed to pass before repeated testing.  Non-specific reactions can 
occur with skin testing.   
 
Serological testing for Johne’s disease (Paratuberculosis) using PPD 
Identification of Johne’s positive animals utilizing serological testing methods continues to 
be a struggling area of diagnostics.  Early studies examined comparisons between the 
complement fixation test (CFT) and PPD skin testing primarily due to concerns that the two tests 
may interfere with each other.  The CFT was initially used by early investigators and the 
polysaccharide antigen used provided strong antigenicity (Annau, 1958; de Lisle et al., 1980).  A 
group in Canada conducted a comparative study and the results indicated that the use of PPD for 
skin testing prior to complement fixation testing did not interfere with performance of the CFT 
(Rice and Konst, 1959).  Rice and coworkers also found that infected animals were more likely 
to respond to skin testing than to the CFT, but they used M. avium antigens in that study (Rice et 
al., 1958).  Two studies in Denmark indicated similar results in that there was a higher response 
rate to skin testing than the CFT (Jorgensen, 1964; Ringdal, 1964).  The two herds involved in 
these studies were identified as infected with avian tuberculosis and so the results may not be 
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specifically comparable to MAP-infected herds.  Around this same time there were testing 
recommendations distributed by the British Veterinary Medical Association in which the use of 
the PPD skin test was the best test option for identifying herds with animals that may be 
subclinical, and that the CFT along with acid fast staining were satisfactory tests for animals 
exhibiting clinical disease (BVA, 1962).   
 
PPD use in gamma interferon testing 
During the time of ELISA development in the early to mid-1990s, significant work was 
concurrently exploring the potential use of MAP PPD in interferon gamma (IFN-γ) assays based 
upon the assay performance for detecting bovine tuberculosis.  Proposals for such use began in 
the early and mid-1990’s with studies comparing ELISA’s with the IFN-γ assay (Billman-
Jacobe, 1992; Vizard et al., 1992; Wood, 1989).  An additional study used data from both 
clinical and subclinical animals, along with negative controls, and the data indicated the IFN-γ 
values were substantially higher in subclinical animals when compared to the negative control 
group (Stabel, 1996).  The ability to detect subclinical infections in calves less than 15 months of 
age was shown to be problematic due to induction of non-specific IFN-γ production in natural 
killer cells (Jungersen et al., 2002).  A two-year study comparing the IFN-γ assay and serum and 
milk ELISAs proved the IFN-γ assay has a greater sensitivity than the available ELISAs, but 
difficulties were encountered when used for testing young animals one to two years of age (Huda 
et al., 2004).   
A possible improvement to the IFN-γ assay by addition of interleukin-12 as a stabilizer to 
blood samples indicated this step could enhance IFN-γ levels, but at the same time increased 
non-specific IFN-γ production (Jungersen, 2005).  Additional work by Jungersen indicated that 
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the IFN-γ assay should be used as a herd based testing protocol to evaluate the level of exposure 
to MAP rather than indicating the infectious status or future disease progression of individual 
animals (Jungersen et al., 2012).  The evaluation of 14 recombinant antigens for use in the IFN-γ 
assay resulted in findings that MAP PPD had higher levels of responses from samples of both 
infected and non-infected animals in contrast to the higher specificity observed for these novel 
antigens in serological assays (Mikkelsen et al., 2011).  Another important aspect of the 
Mikkelsen et al. study is that three antigens had no homologue in the M. avium nor M. bovis 
genomes. 
Development of the IFN-γ assay allowed researchers an additional tool for examining the 
bovine immune response to MAP infections.  Along with these advances the importance of the 
antigenic characteristics of MAP PPD proved a vital component for successful IFN-γ assay 
development and performance.  Continued evaluation of MAP PPD antigenic components may 
reveal possible improvements to the IFN-γ assay.   
 
Field trials related to PPD use 
Many early studies evaluated the effectiveness of Johnin in naturally infected dairy cattle 
in herds of substantial size.   Difficulties with the specificity and sensitivity of the Johnin product 
continued to cause concern, but also indicated the importance of skin testing as a means to 
identify positive animals in the early stages of infection (Merkal, 1968; Sikes, 1953; Sikes et al., 
1951).  The 1968 study by Merkal involving the comparison of multiple test methods began a 
transition to fecal culture as the gold standard test in Johne’s diagnosis from actively shedding 
animals.  However, the use of the skin test was found to still be of value in identifying positive 
animals. 
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A heavily infected dairy herd was tested utilizing MAP PPD approximately every three months 
over a period of time exceeding two years (Johnson, 1950).  Even with frequent skin testing 
followed by the removal of positive animals the prevalence of infection continued to be 
maintained.  Eventually it was concluded that the rate of infection was high enough that testing 
and removal of positive animals at three month intervals was not sufficient to prevent the spread 
of infection.  However, an important aspect of this study was that there were no false positive 
animals identified as long as close attention was given to the degree of induration measured 
during skin testing.   
Studies in Canada reported successful use of PPD in 8 herds to eradicate Johne’s disease in half 
of the enrolled herds (Konst and McIntosh, 1958a, b).  This successful conclusion was based 
solely on there being no further reoccurrence of clinical signs of Johne’s disease in the herds. 
There were continued concerns related to the use of PPD in heavily infected herds or during 
particular stages of infection.  A five-year study in Alabama was conducted using one-time PPD 
skin testing and examination of tissue smears collected at slaughter (Larsen et al., 1963).  Skin 
test results from this study reached 51% sensitivity and 55% specificity.  The quantity of infected 
animals in this herd was high yet the results supported earlier studies that the sensitivity of the 
MAP PPD skin test may not be optimal in such situations where advanced stages of infection 
were evident in a herd.  However, an important advancement from this study was that an 
induration cutoff of 3 mm was established and anything short of that may have an effect on the 
sensitivity of the skin test results.   
A study in Canada suggested that the skin test was useful for identifying subclinical or 
preclinical animals, but was not optimal for identifying clinical animals (de Lisle et al., 1980).  
Animals were tested using both skin test and complement fixation and any positive animals to 
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both tests were culled from the herd.  Skin testing was conducted using two measurement criteria 
in which animals with indurations of both greater than and less than 3 mm were recorded.  When 
test sensitivity was calculated using a cut off with greater than 3 mm induration, the overall skin 
test sensitivity was only 5% with a 94% specificity.  If data for all animals with positive skin 
reactions was considered, the test sensitivity increased to 48% but showed only a 32% 
specificity.  Neither set of test criteria contributed confidence for overall use of the MAP PPD 
skin test. 
A study in India compared testing for cattle using the skin test to selected available serological 
tests (Paliwal, 1987).  Results were similar to previous studies in which the skin test performed 
well for identifying preclinical diseased animals, but once the animals transitioned to expression 
of clinical symptoms, the skin test did not perform as well as the serological assays. 
A Netherlands study conducted intradermal skin testing on paratuberculosis vaccinated animals 
between the ages of five and 14 months (Wentink et al., 1993).  Similar to previous studies, 
negative skin test results occurred significantly more often in animals found positive post 
mortem by histology or culture.  The combined data from these studies supported the use of a 
serological assay for detecting shedding or clinical stage animals, and began the emphasis toward 
pursuit of serological assays in place of the PPD skin test.  The results of these studies were 
further confirmed as the immunology of MAP infections in cattle became more understood.  The 
early stages of infection involve T helper type 1 (Th1) polarization of the immune response 
along with MAP-specific IFN-γ production (Stabel, 2006; Stabel and Whitlock, 2001).  This 
finding correlates with the ability of PPD skin tests to detect infected animals in the preclinical or 
subclinical stages of infection prior to fecal shedding.  As MAP infection progresses and fecal 
shedding and clinical signs appear, there is a transition to a T helper type 2 (Th2) immune 
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response with the production of MAP-specific antibodies (Stabel, 2006).  During this transitional 
stage accurate diagnosis can be difficult and the use of multiple testing strategies proves most 
useful (Koets et al., 2002; Nielsen and Toft, 2008).  Collectively, these studies support the earlier 
observations where PPD skin test sensitivity decreased or was non-existent for animals in the 
clinical stages of infection. 
 
Current PPD production methods at the National Veterinary Services Laboratory 
The National Veterinary Services Laboratories (NVSL) produces PPD products from M. 
bovis, M. avium subsp. avium, and MAP.  The greatest emphasis is for M. bovis and M. avium 
subsp. avium PPD products in support of the USDA Bovine Tuberculosis Eradication Program.   
PPD production protocols are similar for the three different products, with the primary 
differences being in media composition used for culture propagation and the chemical used for 
protein precipitation.  MAP PPD production is conducted by using MAP 19698 grown in Reid’s 
Media supplemented with Mycobactin J.  Production cultures are incubated for approximately 
10-12 weeks at 37oC and are examined regularly for quality of a floating pellicle and 
contamination.  Following incubation, production flasks are autoclaved at 121oC for 30 minutes 
and allowed to cool overnight.  Cells are then removed by coarse filtration through sterile 
cheesecloth within a funnel to produce a culture filtrate (CF).  Proteins within the CF are 
precipitated with the addition of one part of 40% TCA to nine parts of CF and mixed thoroughly 
during addition.  This suspension is then allowed to set overnight at room temperature and the 
supernatant is removed the next day by aspiration and centrifugation.  The resulting protein 
precipitate is washed twice with 1% TCA followed by multiple washes with 10% sodium 
chloride solution to remove the TCA.  The final protein suspension is then dissolved in a sodium 
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phosphate chloride buffer and adjusted to a final pH of 7.0 + 0.1 prior to final filter sterilization.  
The concentrate is then stored at a refrigerated temperature during protein determination testing 
using the micro-Kjeldahl method.  The final PPD product is then adjusted to 1.0 mg/ml of 
protein and phenol is added to a final concentration of 0.5% prior to final sterility testing. 
Overall the NVSL distributes over one million doses of M. bovis caudal fold tuberculin 
annually.  Distribution of MAP PPD domestically is minor in comparison and is used in the field 
on a very limited basis.  Contributing to the reduced demand for MAP PPD is the requirement 
for producers wishing to enroll in the USDA Voluntary Johne’s Disease Control Program to use 
either serological assays or fecal culture, or a combination of both, for determination of a herd’s 
eligibility for the program, which is no longer funded by the USDA. With the emphasis on 
culture and serological testing as the approved testing methods, the number of herds utilizing 
skin testing has decreased.  In contrast to domestic requests the NVSL has had increased requests 
for MAP PPD from India and the United Kingdom.  The ability to produce a consistent and well-
characterized MAP PPD may allow for expanded use of the INF-γ assay and increase demands 
in the future. 
 
Advances in PPD protein proteomic analysis 
Current PPD production processes are time consuming and laborious accompanied with 
difficulties related to lack of product reproducibility.  The slow growth requires approximately 
three months prior to being able to initially harvest flasks containing appropriate growth.  When 
adding in downstream processing, sterility testing, and potency testing, a production timeline can 
have an additional two to three months added on to final product release.  The five to six month 
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production timeline can be impactful should a production lot not pass all quality control testing, 
causing a long-term setback to providing additional product for use.   
Because of difficulties associated with PPD production and the lack of new PPD research, 
it was decided to pursue improved PPD reagent production that is more efficient and 
reproducible while maintaining required potency characteristics.  As a first step toward this goal, 
studies were conducted to determine the PPD composition and what components may be used to 
replace the current crude suspensions.  
Proteomic analysis of PPD preparations has taken on more emphasis in recent years 
primarily due to improvements in proteomic techniques, but it is still a relatively new area of 
investigation with only a few published studies.  Interest in Mycobacterium tuberculosis (MTb) 
PPD has led to the discovery of a number of conserved proteins between MTb PPD, M. bovis 
PPD, and M. avium PPD (Cho et al., 2012; Prasad et al., 2013).   
A study comparing proteomic protein findings between MAP PPD, M. bovis PPD, and M. 
avium PPD identified 156, 132, and 95 proteins, respectively from each of the three PPD 
preparations (Santema et al., 2009).  However, an interesting finding of this study was that three 
of the proteins selected for further immunological study showed that the proteins were non-
reactive in lymphocyte proliferative assays (cellular immune responses), but yet resulted in very 
good serum antibody responses (humoral immune responses).  Another research group 
conducted proteomic characterization of five in-house MAP PPD preparations along with eight 
additional MAP PPD preparations, one M. avium PPD, and one M. bovis PPD.  One of these 
MAP PPDs from the NVSL was found to have insufficient protein quantity for further analysis 
with the remaining 13 preparations having between 76 and 134 proteins identified within each 
PPD (Wynne et al., 2012).  Resulting protein composition differences between preparations were 
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most likely due to MAP strain differences and the culture age when harvested for protein 
preparation. 
Continued genetic investigation of MAP strains used for PPD production and various 
antigen production processes has resulted in the identification of specific strain and isolate 
differences that may influence protein expression and immunogenicity of antigenic preparations 
(Bannantine et al., 2007; Gumber et al., 2009; Gumber and Whittington, 2009; Radosevich et al., 
2007; Semret et al., 2006; Weigoldt et al., 2011).   
Monoclonal antibodies to the 35 kilodalton (kDa) major membrane protein were purified 
and characterized in 2007 by immunoblotting, epitope mapping, and immunofluorescence 
microscopy (Bannantine et al., 2007).  Cross reactivity observed in immunoblot experiments 
with the use of various mycobacterial species indicated that the 35 kDa was not species specific 
and there existed shared immunological determinants between mycobacteria compared in the 
evaluation.  Many of these were members of the M. avium complex (MAC), though the 
comparison also included fast growing mycobacteria in which such cross reactivity may not have 
been initially anticipated. 
Changes in protein levels expressed in response to varying environments was revealed by 
exposure of MAP isolates to varying incubation temperatures, fluctuations of temperature, 
hypoxia, and nutrient availability (Gumber et al., 2009; Gumber and Whittington, 2009).  
Evidence that protein expression variations exist due to changing environmental conditions 
offered insight into possible important interactions of MAP within the host.  Host cell and 
immunological responses may provide similar environmental stressors affecting protein 
expression during various stages of infection.  This information would play an important role in 
determining specific proteins with improved diagnostic potential.   
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Comparison of MAP strain K-10 and a field isolate from a cow exhibiting clinical signs of 
Johne’s disease revealed there were marked differences in protein expression when examined by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry (Radosevich 
et al., 2007).  Differences in protein expression were related to differences in passage level of the 
two isolates.  What was not clear from the study is how the specific protein differences may 
affect MAP virulence or the specific role the various proteins play in cell-mediated immune 
responses.  This information could be important in future improvements to PPD production if it 
is determined that low passage cultures provide optimal protein expression related to cell 
mediated immune response recognition. 
By using DNA microarray analysis Semret and colleagues identified 14 large sequence 
polymorphisms that distinguish M. avium from MAP (Semret et al., 2004).  The authors 
speculated that these sequence polymorphisms may be related to MAP mycobactin dependence.  
Further work with various MAC isolates involved in PPD production identified a large sequence 
polymorphism (referred to as LSPjn) that was absent in seven MAP strains (Semret et al., 2006).  
Deletion of this particular locus is thought to have occurred due to continual laboratory passage 
as it was shown to be intact in field isolates.  Two studies involving ovine Johne’s diagnostics 
indicated increased test sensitivity when using PPD produced from isolates with the locus intact 
(Robbe-Austerman et al., 2006a; Robbe-Austerman et al., 2006b).  Continued work to establish 
improved production processes including the use of well characterized MAP strains is an 
important aspect to be considered from these studies. 
Additional information related to differential expression of specific MAP protein 
components within the host was provided in a study using MAP isolates from three cows with 
clinical Johne’s disease (Weigoldt et al., 2011).  A large number of membrane-associated 
28 
 
proteins and culture-derived membranes were identified using mass spectrometry.  Four proteins 
were identified as being present only in the membrane-associated preparations.  This information 
could prove valuable when determining possible proteins to be included in a well characterized 
PPD since such membrane-associated proteins would offer the best possibility as the first 
immunologically recognized MAP components during establishment in the host.   
Additional work related to the specific immunological responses to the various identified 
proteins combined with the differences in conditions related to protein expression could help 
decipher specific changes to production processes and aid in development of improved PPD 
preparations.   
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Abstract 
Mycobacterium avium subsp. paratuberculosis (MAP) purified protein derivatives 
(PPDs) are an immunologic reagent prepared from the cultured filtrate of MAP ATCC strain 
19698.  PPD was produced using MAP ATCC Strain 19698 in Povitsky bottles and Erlenmeyer 
flasks.  Traditional production consisted of floating culture incubation at 37oC, live organism 
inactivation by autoclaving 30 minutes at 121oC, and coarse filtration to remove cellular 
debris.  An alternative production method was developed involving removal of the autoclaving 
step during the production process.  Proteins in both production methods were subsequently 
precipitated by adding trichloroacetic acid to a final 4% concentration.  Culture production in 
Erlenmeyer flasks was superior to that of traditionally used Povitsky bottles as determined by 
floating culture mat density and time required for growth.  Defined protein bands on SDS-PAGE 
gels were masked by smearing of the gel tracks containing PPD produced by the traditional 
method whereas protein bands were evident in the alternate PPD preparations.  Results indicate 
that the current production procedure and an alternate production method produced PPD 
equivalent to the reference NVSL PPD Lot 9801.  PPD preparations will be used for further 
analysis to define protein components and identification of possible antigenic components. 
 
Key Words:  bovine, paratuberculosis, purified protein derivative, Johne’s disease, protein 
precipitation, culture filtrate. 
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Introduction 
  Production of purified protein derivative (PPD) from MAP, has historically been 
problematic because of unique culture requirements of floating cultures and maintaining floating 
mats during the extended incubation period.  This particular method of floating cultures is used 
to allow for expression of surface proteins and proteins which may be secreted and available 
within the growth media.   This important reagent is used for skin testing (Robbe-Austerman et 
al., 2006; Wren, 1998) and has been used as a stimulating antigen in research involving the 
gamma interferon test for Johne’s disease (Billman-Jacobe, 1992; Gwozdz, 2000; Kalis et al., 
2003; Robbe-Austerman et al., 2007; Stabel, 1996; Stabel and Whitlock, 2001).  Attempts at 
improvements of production methods can be traced back to the early 1900s with modification of 
growth media to a synthetic media to eliminate possible reactive animal protein from the media 
preparation (Dunkin, 1933; Watson, 1935).  In addition, the production methods and time 
required for cultures to meet acceptable yield characteristics can lend to difficulties associated 
with efficiently producing a quality PPD.  Early production methods using heat concentrated 
culture media were later modified to production of PPDs utilizing protein precipitation methods 
(Glover, 1941; Johnson, 1944; McIntosh and Konst, 1943; Watson, 1935).  Complicating matters 
further, until recently the defined immunogenic components of PPD preparations had yet to be 
characterized.  In recent years, two laboratories conducted proteomic analysis of PPD 
preparations (Santema et al., 2009; Wynne et al., 2012) providing information on some of the 
PPD protein components that may contribute to improvements in the specificity of the product.  
Development of a consistent and defined reagent with a high degree of specificity in early 
disease detection similar to that observed for bovine tuberculosis was the goal in early studies of 
PPD production (Johnson and Pratt, 1944). 
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Over time, various Mycobacterium avium complex (MAC) strains served as the source of 
antigen preparations used in PPD production and it was subsequently discovered that in some 
cases multiple strains were used in those PPD preparations (Dunkin, 1928; Watson, 1935).  
Concern over possible variations in strain differences has led to closer scrutiny of strain 
characteristics, and advances in analysis of culture stocks has found that in some cases 
Mycobacterium avium subsp. avium has been used in production of MAP PPD (Semret et al., 
2006).   
The objective of this investigation was to produce PPD by the traditional method and by 
an alternative method and to characterize protein composition and biological activity.  The 
traditional production method of heat-killing MAP cultures and subsequent protein precipitation 
from the culture filtrate was used for the production of four different PPD lots.  These four lots 
were assessed and evaluated through culture growth characteristics, PPD protein concentration, 
SDS-PAGE analysis, and reactivity against rabbit antiserum raised against an established PPD 
lot currently used in the field.  In addition, two PPD lots were produced using an alternate 
production method and were assessed and evaluated through culture growth characteristics, PPD 
protein concentration, and SDS-PAGE analysis. This study was undertaken as a first step to 
evaluate current production methods for obtaining consistent PPDs, and provide an initial PPD 
from an alternative production method toward the goal of improving the PPD, which is better 
defined for in-vivo and in-vitro diagnostic purposes. 
 
Materials and Methods 
Bacterial cultures.  M. paratuberculosis strain ATCC 19698 and two bovine field isolates from 
Iowa were selected for use in the PPD production process.  MAP 19698 inoculum was 
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transferred from a starter culture grown on Herrold’s Egg Yolk plus Mycobactin J (HEY+MJ) 
agar slants and Reid’s media.  The two bovine field isolates, #392 and #455, were subcultured 
from TREK para-JEM culture bottles (Thermo Scientific) onto three different media:  1) 
Herrold’s Egg Yolk Agar with Mycobactin J (HEY+MJ), 2) 15 ml of Middlebrook 7H9 broth 
containing oleic acid supplement and glycerol supplemented with Mycobactin J (OADC broth) 
and, 3) modified Reid’s media supplemented with Mycobactin J (NVSL Media Recipe 41020).  
Neither field isolate grew well upon subculture within any of the three media, and thus were 
unsatisfactory at the time for PPD production.   
Three to four loopfuls of ATCC 19698 pellicle from a starter culture were subcultured 
into modified Reid’s media in either Povitsky bottles or Erlenmeyer flasks.  Transferred pellicle 
material was floated onto the surface of the Reid’s media.  The inoculated bottles and flasks were 
incubated at 37oC for 10 to 12 weeks for use in future PPD production lots produced in 2008.  
Any bottles or flasks in which the floating mat would sink during incubation were discarded and 
not used in the PPD production process.  Such individual culture containers were not used in 
further processing because of the inability of adequately predicting protein expression within the 
culture filtrate during the decreased growth period and decreased cell growth. 
PPD production, traditional.  The reference MAP PPD (NVSL 9801 without phenol) used in 
this investigation was previously produced at the NVSL (Steadham et al., 2002). Four PPD lots 
(0801A, 0801B, 0802, 0803A) were produced sequentially in 2008 as previously described 
(Haagsma and Angus, 1995; Steadham et al., 2002).  Following incubation, bottles or flasks were 
autoclaved at 121oC for 30 minutes and allowed to cool at room temperature overnight.  Cells 
were removed from the medium by straining the suspensions through sterile cotton mesh lining a 
sterile funnel, and culture filtrate (CF) was collected in a sterile flask. 
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Proteins in the culture filtrate were precipitated with the addition of 1 part 40% 
trichloroacetic acid (TCA) to nine parts of CF.  The suspension was mixed well and allowed to 
incubate overnight without stirring at room temperature.  The next day a large portion of the 
supernatant was removed by aspiration and discarded.  The remaining supernatant was mixed 
well with the precipitated proteins and transferred to centrifuge bottles.  The bottles were 
centrifuged at 2500 x g for 15 minutes to pellet precipitated proteins.  The supernatant was again 
discarded, and the remaining pellets were washed with 1% TCA two times, and then with 10% 
sodium chloride as the final wash.  The precipitate was dissolved in a phosphate chloride buffer, 
and the final pH was adjusted to 7.0 + 0.1 with 1 N sodium hydroxide.  The final suspension was 
sterile filtered through a 0.22 micron cartridge filter (Pall Supor DCF) and stored at 4oC until 
further use.  Purity testing was conducted in accordance with the Code of Federal Regulations, 
9CFR part 113.26. 
PPD production, alternate.  Two additional PPD lots (0901 and 0902) were sequentially 
produced in 2009 removing the autoclaving step and utilizing sterile filtration to ensure the 
removal of bacterial cells and sterility of final product.  In brief, the revised protocol was 
conducted by doing a coarse filtration of the live MAP cells from the growth suspension and 
collecting the subsequent CF into a sterile flask.  This CF was then sterile filtered through an in-
line 0.5 µm cartridge filter (Pall Preflow DCF) followed by an in-line 0.22 µm cartridge filter 
(Pall Supor DCF).  The culture filtrate was then processed as described for the traditional 
production method.  The first lot produced through the alternative method had the final 
suspension sterile filtered through a 0.22 micron cartridge filter, and stored at 4oC until further 
use.  The second lot produced through the alternative method had the final 0.22 micron filtration 
step removed from the workflow.  Purity testing was conducted in accordance with the Code of 
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Federal Regulations, 9CFR part 113.26 for both lots.  Lot 0902 was initially split into two 
production processes to designate respective bulks retained from the two different bacterial 
harvest start dates.  These lots are indicated as 0902A and 0902B when differentiation is 
required. 
Protein concentration assay.  Protein measurements of the final PPD preparations were 
conducted utilizing the Pierce microplate BCA protein assay procedure according to the 
manufacturer’s directions.  Assay plates were read on a VersaMax microplate reader at a 
wavelength of 562 nm.  Protein concentrations were calculated using SoftMax Pro software from 
a standard curve of bovine albumin protein standards. 
SDS-PAGE.  Pre-cast 4-12% Novex Bis-Tris gels (Invitrogen, 12 well, 1 mm thickness) or 
precast 10% Novex Bis-Tris gels (Invitrogen, 12 well, 1 mm thickness) were used for SDS-
PAGE separation of PPD preparations.  MAP PPDs, Mycobacterium bovis (M. bovis) PPD, and 
Mycobacterium avium subsp. avium (M. avium) PPD were standardized to approximately 1.0 
mg/ml before loading 15 µg/well onto SDS-PAGE gels.  The PPDs were prepared by the 
addition of 5 μl of sample buffer (Invitrogen NuPage LDS Sample Buffer) to 15 μl of PPD and 
then heated at 70oC for ten minutes before loading the full 20 μl of sample.   
Electrophoresis was conducted in an Invitrogen XCell SureLock Mini-Cell system at a 
constant current of 125 mA for 35 minutes.  Invitrogen SeeBlue Plus2 prestained molecular 
weight standards served as markers for molecular weight determination.  Gels were stained with 
Invitrogen Novex Colloidal Blue Stain according to the manufacturer’s directions. 
The 4-12% Novex Bis-Tris gels (Invitrogen, 1 well, 1 mm thickness) were used for 
immunoblot analysis. MAP PPDs were prepared as previously described by the addition of 175 
μl of sample buffer (Invitrogen NuPage LDS Sample Buffer) to 225 μl of PPD for each 500 μl of 
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preparation.  Designated wells were loaded with 500 μl of reduced sample.  Electrophoresis was 
conducted in an Invitrogen XCell SureLock Mini-Cell system at a constant current of 125 mA 
for 35 minutes. 
Rabbit immunizations.  PPD Lot 9801 was combined with TiterMax Gold adjuvant and 
administered subcutaneously at dosage volumes of either 0.5 ml or 1.0 ml.  Inoculations were 
administered on days 0, 14, 28 and 56.  Blood collections were taken on days 0, 14, 28, 56, and 
77.  Rabbits were euthanized and exsanguinated on day 86 for the final blood collection.  One 
rabbit (7436) was euthanized partway through the study and serum samples previously collected 
from this rabbit were not included in further work. 
Cattle sera.  Sera were obtained from cattle housed at the NVSL and also from naturally 
infected cattle from private herds.  Naturally infected cattle were confirmed serologically 
positive on both the Prionics Paracheck® and IDEXX MAP ELISA assays.  Positive cattle were 
also confirmed culture positive by fecal culture on HEY-M.  Negative cattle samples were from 
negative control source animals within the NVSL and from MAP negative confirmed production 
herds outside the NVSL (Table 1).  Negative animals were confirmed by culture and serology by 
the same procedures as the positive cattle. 
Immunoblot analysis.  Electrophoretic transfer of proteins onto nitrocellulose was performed 
using the Invitrogen XCell II Blot Module and Invitrogen NuPAGE transfer buffer at 160 mA 
for one hour.  After transfer completion, membranes were blocked with Sigma Western Blocker 
solution at room temperature for one to two hours with rocking.  Antisera from immunized 
rabbits were diluted 1:500 in blocker solution and incubated with the membranes at room 
temperature with rocking for approximately 60 minutes. Membranes were washed three times 
with Trizma-buffered saline plus 0.5% Tween 20 (TBS-T).  The membrane was incubated for 
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approximately 60 minutes at room temperature on a rocker with peroxidase-labeled goat anti-
rabbit IgG (Jackson Immunoresearch Affini-Pure) as the secondary antibody diluted 1:2000 in 
blocker.  The membrane was then washed three times with TBS-T and developed utilizing Sigma 
TMB Substrate according to the manufacturer’s directions. 
Evaluation of the PPDs from the two different production methods was also conducted 
using 16 ELISA positive and two ELISA negative cattle sera.  Two individual membranes were 
prepared in parallel, with one membrane developed with a TMB substrate and the second 
membrane for chemiluminescent detection.  The cattle sera were diluted 1:20 in blocker solution 
for both blot preparations and incubated with the membranes at room temperature with rocking 
for approximately 60 minutes.  Membranes were washed three times with TBS-T.  At this point, 
one set of membranes were incubated for approximately 60 minutes at room temperature on a 
rocker with peroxidase labeled rabbit anti-bovine IgG (Jackson Immunoresearch Affini-Pure) 
diluted 1:2000 in blocker.  Membranes were then washed three times with TBS-T.  Membranes 
were developed in Sigma TMB Substrate according to the manufacturer’s directions.  The 
second set of membranes were incubated with HRP conjugated Protein A as a secondary 
antibody, diluted 1:20,000 in blocker, for approximately 60 minutes at room temperature on a 
rocker.  Membranes were then washed three times with TBS-T.  Membranes were developed 
with SuperSignal Chemiluminescent substrate for 5 minutes. 
 
 
Results 
Bacterial culture characteristics.  Mycobacterium avium subsp. paratuberculosis strain ATCC 
19698 grew well in Reid’s media in both the Povitsky bottles and Erlenmeyer flasks (Figures 1 
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and 2).  Although historically at the NVSL, cultures for PPD production were grown in Povitsky 
bottles, growth rates were slightly faster in the Erlenmeyer flasks, taking approximately 10 
weeks to produce a thickened, quality pellicle or floating mat suitable for harvest.  The Povitsky 
bottle cultures also produced good floating mats, but typically were not ready for harvest until 12 
weeks post-inoculation.  In addition, the Povitsky bottle cultures had a greater tendency to have 
mats begin to fall in small sections near the end of the incubation period.  Overall the Povitsky 
bottles produced 0.027 grams of wet weight cells per ml of media versus Erlenmeyer flask 
production of 0.032 grams of wet weight cells per ml of media at 12 and 10 weeks, respectively 
(Table 2).   
The two bovine MAP field isolates, subcultured onto HEY+MJ, OADC broth, and 
modified Reid’s media, did not yield productive growth within any of the three different media 
types.  Eventually growth was detected on HEY+MJ, but the colony formation was not favorable 
for transfer into Reid’s media for attempting to produce a floating culture.  These field isolates 
were simply not laboratory adapted for this procedure.  Therefore, no additional work was 
conducted with these two isolates. 
PD production and protein concentration.  The four lots of PPD (0801A, 0801B, 0802, 
0803A) produced by the traditional production process all yielded acceptable protein 
concentrations at a minimum of 1 mg/ml.  Protein concentrations ranged between 1.1 to 2.1 
mg/ml and suspension characteristics were typical of previous PPDs, yielding a light brown to 
tan final suspension.  Sterility testing of each lot did not yield growth of any contaminants and 
thus final QC evaluations were deemed acceptable.   
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PPD Lot 0901, processed through an alternative method, was not acceptable for 
additional analysis after the final filtration step.  During the final sterile filtration, multiple filters 
were required to complete the process resulting in an unsatisfactory loss of protein content.   
PPD Lot 0902A and 0902B, also processed through an alternative method, yielded a final 
suspension of a dark tan coloration and overall acceptable appearance.  The final protein 
concentration was approximately 1.2 mg/ml, and this preparation was confirmed sterile. 
SDS-PAGE.  SDS-PAGE analysis of PPD Lot 9801 yielded results showing obvious protein 
smearing and the lack of any discernable protein banding patterns (Figures 3 and 4).  This result 
is similar to that observed in other laboratories (Cho et al., 2012; Rennie et al., 2010).  Lots 
0801A, 0801B, 0802, and 0803A yielded products with less protein smearing, but smearing was 
still significant masking the presence of definable protein bands (Figures 3 and 4).  Similar 
protein smearing characteristics have also been noted in earlier work during examination of both 
M. bovis and M. avium PPD preparations at the NVSL.  The appearance of these “dirty” gel 
tracks suggested the gels might be overloaded with protein.  Additional dilutions of PPD 
preparations were analyzed in an attempt to reduce the presence of protein smearing and resolve 
protein bands.  With further dilution of the PPD preparations the “background” did decrease, and 
lightly stained bands initially obscured by the protein smearing could be detected for Lot 0801A, 
0801B, 0802 whereas 0803A still showed the same characteristic smearing as an undiluted 
product (Figure 4).  In contrast, PPD Lot 0902 yielded eight distinct protein bands common 
between the two different SDS-PAGE gels and showed little to no smearing (Figures 3 and 4).  
Common identifiable protein bands within the two gels corresponded to sizes of approximately 
145 kDa, 50 kDa, 40 kDa, 34 kDa, 25 kDa, 20 kDa, 18 kDa, and 12 kDa.  The 4-12% gel 
showed two additional protein bands at approximately 30 kDa and 15 kDa, while the 10% gel 
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had an additional band with an approximate size of 48 kDa.  In addition, similar protein bands 
between the MAP PPD and an M. bovis PPD, were detected at approximately 25 kDa and 12 
kDa (Figures 3 and 4).  The M. bovis PPD protein bands were more diffuse and matched most 
closely to those particular protein bands in the MAP PPD preparations.  No specific protein 
bands were observable in the M. avium PPD preparation.   
Immunoblot analysis.  Protein smearing, initially evident in the colloidal blue staining of the 
SDS-PAGE gels, contributed to problems with obtaining proper sera dilutions for detection of 
any specific protein reactions.  Sera reactions to the smearing evident throughout each lane did 
indicate moderate to strong immune response by a majority of the rabbits.  Five rabbit sera 
(rabbits 7429, 7430, 7432, 7437, and 7438) were evaluated against PPD Lot 0801A, 0801B, 
0802, and 0803.  Results for all five rabbit sera did produce light bands that were partially 
obscured at approximately 34 kDa, 18 kDa and 15 kDa.  This indicated a more specific reactivity 
to the four new production lots in comparison to reactivity against PPD Lot 9801.  Immunoblot 
results of rabbit antisera showed moderate to strong immunological reactivity when evaluated 
against PPD Lot 0902, adding support that removing the autoclaving step from the production 
process was not detrimental to the immunoreactivity.  Serum from rabbit 7430 did result in a 
band at approximately 48 kDa that could be observed within the blots regardless of the detection 
method used.  No other protein bands could be differentiated using anti-Lot 9801 PPD antibody 
against PPD Lot 0902 antigen by immunoblot.  However, all inoculated rabbits did show 
reactivity against PPD Lot 0902.  Sera from rabbits 7429, 7432, 7433, 7435, 7437, and 7438 
exhibited moderate reactivity and sera from rabbits 7430, 7431, and 7434 exhibited strong 
reactivity.  One rabbit (7434) exhibited high reactivity with the strongest response toward higher 
molecular weight proteins within the PPD suspensions (Figure 5).   
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Immunoblots utilizing cattle sera yielded comparable results for Lot 9801 and Lot 0902.  
One difference noted was that blots of lot 0902 antigen resulted in specific protein bands being 
identified in the reactions (Figures 6 and 7).   Protein bands were often more evident on blots 
developed in the TMB substrate whereas the same bands were not as evident utilizing 
Supersignal.  These results further suggest that removing the autoclaving step in the production 
process is not detrimental to the immunological characteristics of the MAP PPD.  
    
Discussion 
The primary objective of this study was to test the effect of heat treatment on PPD 
preparations by examining certain performance characteristics of PPD preparations.  To achieve 
this objective, we measured protein concentrations and analyzed preparations by SDS-PAGE and 
immunoblot analysis.  We found that the autoclaving step may not be necessary in producing 
PPD; but it is not known if this affects the potency of the PPD.  In addition, the effect of 
autoclaving perhaps leads to increased protein fragmentation, which contributes to the smearing 
observed during SDS-PAGE analysis and was not a productive method to define differences 
between these preparations.  Further work must be done to define the protein components and 
measure delayed-type hypersensitivity potency within these modified preparations. 
With additional research in identifying the proteomic profiles of MAP, the need to 
identify specific protein components of the PPD has increased in recent years.  Current 
production methods require the establishment of a floating mat or pellicle for PPD production.  
This particular method allows for expression of surface proteins and proteins which may be 
secreted and available within the growth media.  This method should allow for a majority of the 
proteins present to be surface proteins, rather than cytosolic proteins.  Because surface proteins 
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would be the first antigenic components encountered in an infected animal, this should allow for 
more specific reactions as well as possibly earlier detection.  Studies involving secreted antigens 
have recognized the importance of such components in paratuberculosis diagnosis (Cho and 
Collins, 2006; Willemsen et al., 2006).  The interest in secreted antigens has primarily involved 
their significance for use in enzyme-linked immunosorbent assays (Facciuolo et al., 2013; Shin 
et al., 2008).  However, the significance of these culture filtrate proteins had not been examined 
more closely in regards to components within PPD preparations nor their significance in cell 
mediated immune responses.  
Current culture production methods worked equally well in either Povitsky bottles or 
Erlenmeyer flasks.  These data would suggest that the specific growth containers should not have 
an impact on final product quality, but should allow for sufficient surface area for the formation 
of a floating mat.  The adequate formation of a stable and thick floating mat of cells is likely to 
be the greatest influence on the quality of final product. 
SDS-PAGE analysis of different PPD preparations produced by traditional methods has 
shown little to no specific protein banding characteristics.  It was thought this may be a result of 
the autoclaving step involved in the production process.  Results indicate that removing the 
autoclaving step within the procedure results in a final PPD product with better defined protein 
bands in SDS-PAGE analysis.  While some proteins could be visualized to a limited extent 
within PPD preparations that were autoclaved in the production method, these proteins were 
obscured and difficult to visualize.  The modification of the current production method may 
allow for a better defined PPD product.  Further analysis of specific proteins observed in SDS-
PAGE gels from Lot #0902 should be conducted to identify possible immunogenic proteins and 
support possible changes to production methods. 
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Immunoblot analysis was able to identify three antigenic proteins against rabbit antisera 
raised against PPD lot 9801.  One of these proteins (34 kDa) was also identified readily on SDS-
PAGE analysis of the different PPD preparations, except for PPD Lot 9801.  This result would 
indicate a possible dominant protein which may be contributing to the identification of Johne’s 
positive animals through the use of PPDs in field testing.  However, how these particular three 
reactive proteins may relate to a cell mediated immune response, versus a humoral immune 
response, is not yet known.  It is not initially known why no specific protein bands could be 
visualized within the PPD Lot 9801 immunoblot preparation compared to the recent PPD 
preparations.  This may relate to the increased number of protein fragments which result from the 
traditional production method.  However, sera from the inoculated rabbits did indicate reactivity 
as having protein smearing similar to what is observed within gels, but the exact immunogenic 
properties of these proteins or protein components is still unknown.   
Overall, the current traditional production method should be further examined to provide 
a final product which can more easily identify proteins produced within culture supernatants that 
may serve as dominant cell mediated immune response components.  The development of the 
alternative production method provided a PPD which was more conducive to analysis by SDS-
PAGE and immunoblot assays; however, more work needs to be done to determine the effect on 
potency.  Nonetheless, this new method will more readily enable comparisons in protein 
expression between production lots. A first step in additional characterization will be an 
evaluation utilizing the guinea pig potency test to determine if a change in production method 
will yield a product that is as potent as the current PPD Lot 9801 used in the field.  Potency 
testing also assists in determining protein biological activity relating to a cell mediated immune 
response versus a humoral immune response, which will be an important aspect to be considered 
50 
 
to ensure a continued quality product for animal skin testing procedures.  In addition, if specific 
proteins can be determined as dominant components of PPD preparations, the information will 
lend support to establishment of a better characterized reference product for both in-vivo and in-
vitro testing procedures. 
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Table 1:  Cattle Sera used for Immunoblot Evaluation 
 
Table 2:  Mycobacterium avium subsp. paratuberculosis (MAP) cells (wet weight) obtained from 
production flasks/bottles.  Wet weight of MAP cells was consistent between culture vessels. 
 
Figure 1:  Mycobacterium avium subsp. paratuberculosis 19698 floating culture for PPD 
production in Erlenmeyer flask.  Culture is at 8 weeks incubation at 37oC. 
 
Figure 2:  Mycobacterium avium subsp. paratuberculosis 19698 floating culture for PPD 
production in Povitsky Bottle.  Culture is at 4 weeks incubation at 37oC. 
 
Figure 3:  Results of a Coomassie blue stained  4-12% Novex Bis-Tris gel showing 7 PPD 
preparations.  Note the striking differences in PPD produced using the traditional method 
involving autoclaving (lanes 2, 4, and 5 for example) in comparison to PPD produced using an 
alternative production method (lanes 6 and 7).  Lane assignments include:  1- protein standards; 
2-Lot #9801 PPD; 3-Lot 9801 1:10 dilution; 4-Lot 0802; 5-Lot 0803A; 6-Lot 0902A; 7-Lot 
0902B; 8-M. bovis PPD; 9 – M. avium PPD; 10- protein standards. 
 
Figure 4:  Results of a Coomassie blue stained 10% Novex Bis-Tris gel showing 8 different 
PPDs.  Observed the protein smearing of PPD produced by the traditional method involving 
autoclaving (Lanes 2, 6, 8, and 9).  Dilution of PPD clarified protein smearing but did not resolve 
visibility of protein components.  Distinct protein banding is observed in PPD produced by the 
alternative production method (Lane 9).  Lane assignments include: 1- protein standards; Lane 2-
Lot #9801 PPD; Lane 3-Lot 0801A (1:5 dilution); Lane 4-Lot 0801B (1:5 dilution); Lane 5-Lot 
0802 (1:5 dilution); Lane 6-Lot 0803A; Lane 7-Lot 0902A; Lane 8- M. bovis PPD; Lane 9 – M. 
avium PPD; Lane 10- protein standards. 
 
Figure 5:  Results of humoral immune response by immunoblot using sera from rabbits 7429, 
7430, 7431, 7432, 7433, 7434, 7435, 7437, and 7438 diluted 1:500 and PPD 0902.  Odd 
numbered lanes represent day 0 (pre-inoculation) sera and even numbered lanes represent 86d 
post-inoculation samples.  Lane assignments:  1-2:  7429, 3-4: 7430, 5-6: 7431, 7-8: 7432, 9-10: 
7433, 11-12: 7434, 13-14: 7435, 15-16: 7437, 17-18: 7438.  An individual band is visible at 
approximately the mid-way point of lane 4 (Rabbit 7430) indicating reactivity to a specific 
protein component.  Overall responses were weak among a majority of rabbits. 
Figure 6:  Results of cattle sera immunoblots using PPD 0902 produced by an alternative 
production method on the left and PPD 9801 produced by the traditional method on the right. 
Both membranes contained identical serum samples loaded into independent slots. Note that 
distinct immunodominant bands emerge in the alternate PPD preparation.  Lanes 1 – 15 cattle 
positive for Johne’s disease, Lanes 16 & 17 cattle negative for Johne’s disease.  Lane 
assignments correspond to cattle listed in Table 1. 
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Table 1:  Cattle Sera used for Immunoblot Evaluation 
Blot 
Lane 
Animal ID Serological 
Statusa 
IDEXX 
ELISA OD 
Value 
Prionics 
ELISA OD 
Value 
Fecal Culture 
Statusb 
1 Lindenhoff 90 (PA) Pos 0.712 0.465 Moderate 
2 Meyer 1688 (PA) Pos 1.895 1.340 Moderate 
3 Calf? (IA) Pos 2.233 1.599 Neg 
4 $900 (IA) Pos 2.550 1.073 Moderate 
5 1266SS CA (CA) Pos 1.914 0.749 High 
6 2075 (PA) Pos 1.938 1.681 High 
7 874 (MN) Pos 1.565 0.822 Neg 
8 34 (MN) Pos 2.875 3.443 Low 
9 Horst 256 (PA) Pos 1.046 0.5125 High 
10 834 (IA) Pos 1.049 0.234 Low 
11 E22 (IA) Pos 1.920 1.280 Moderate 
12 Charity (WI) Pos 2.146 2.975 Low 
13 Cow 5 (IA) Pos 1.506 0.979 High 
14 Meyer 70 (PA) Pos 2.570 2.982 Low 
15 Lindenhoff 90 (PA) Pos 0.712 0.465 Moderate 
16 Lizzie (IA) Neg 0.006 0.036 Neg 
17 1823 (IA) Neg 0.158 0.089 Neg 
a Serological status determined by IDEXX and Prionics ELISA test results.  IDEXX ELISA OD values read at 450 
nm; Prionics ELISA OD values read at 450 nm. 
b 1-10 Colony forming units/gram (CFU/g) feces = low shedder; 11-50 CFU/g feces = moderate shedder; >50 
CFU/g feces = high shedder. 
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Table 2:  Mycobacterium avium subsp. paratuberculosis (MAP) cells (wet weight) obtained from 
production flasks/bottles.  Wet weight of MAP cells was consistent between culture vessels.   
PPD Lot # Media Volume (ml) Cell Wet Weight 
(gr) Grams Cells/ml Media 
0801A 
(Povitsky 
Bottles) 
6500 212.8 0.033 
0801B (E-
Flasks) 
5800 218.8 0.038 
0802 (E-Flasks) 6000 152.0 0.025 
0803 (Povitsky 
Bottles) 
10,000 210.0 0.021 
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Figure 1:  Mycobacterium avium subsp. paratuberculosis 19698 floating culture for PPD production in Erlenmeyer 
flask.  Culture is at 8 weeks incubation at 37oC. 
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Figure 2:  Mycobacterium avium subsp. paratuberculosis 19698 floating culture for PPD production in Povitsky 
Bottle.  Culture is at 4 weeks incubation at 37oC. 
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Figure 3:  Results of a Coomassie blue stained 4-12% Novex Bis-Tris gel showing 7 PPD preparations.  Note the 
striking differences in PPD produced using the traditional method involving autoclaving (lanes 2, 4, and 5 for 
example) in comparison to PPD produced using an alternative production method (lanes 6 and 7).  Lane assignments 
include:  1- protein standards; 2-Lot #9801 PPD; 3-Lot 9801 1:10 dilution; 4-Lot 0802; 5-Lot 0803A; 6-Lot 0902A; 
7-Lot 0902B; 8-M. bovis PPD; 9 – M. avium PPD; 10- protein standards. 
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Figure 4:  Results of a Coomassie blue stained 10% Novex Bis-Tris gel showing 8 different PPDs.  Observed the 
protein smearing of PPD produced by the traditional method involving autoclaving (Lanes 2, 6, 8, and 9).  Dilution 
of PPD clarified protein smearing but did not resolve visibility of protein components.  Distinct protein banding is 
observed in PPD produced by the alternative production method (Lane 9).  Lane assignments include: 1- protein 
standards; Lane 2-Lot #9801 PPD; Lane 3-Lot 0801A (1:5 dilution); Lane 4-Lot 0801B (1:5 dilution); Lane 5-Lot 
0802 (1:5 dilution); Lane 6-Lot 0803A; Lane 7-Lot 0902A; Lane 8- M. bovis PPD; Lane 9 – M. avium PPD; Lane 
10- protein standards. 
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Figure 5:  Results of humoral immune response by immunoblot using sera from rabbits 
7429, 7430, 7431, 7432, 7433, 7434, 7435, 7437, and 7438 diluted 1:500 and PPD 0902.  
Odd numbered lanes represent day 0 (pre-inoculation) sera and even numbered lanes 
represent 86d post-inoculation samples.  Lane assignments:  1-2:  7429, 3-4: 7430, 5-6: 
7431, 7-8: 7432, 9-10: 7433, 11-12: 7434, 13-14: 7435, 15-16: 7437, 17-18: 7438.  An 
individual band is visible at approximately the mid-way point of lane 4 (Rabbit 7430) 
indicating reactivity to a specific protein component.  Overall responses were weak among a 
majority of rabbits. 
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Figure 6:  Results of cattle sera immunoblots using PPD 0902 produced by an alternative production method on the 
left and PPD 9801 produced by the traditional method on the right. Both membranes contained identical serum 
samples loaded into independent slots. Note that distinct immunodominant bands emerge in the alternate PPD 
preparation.  Lanes 1 – 15 cattle positive for Johne’s disease, Lanes 16 & 17 cattle negative for Johne’s disease.  
Lane assignments correspond to cattle listed in Table 1. 
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Abstract 
Purified protein derivatives (PPDs) previously prepared by two different methods from 
the cultured filtrate of Mycobacterium avium subsp. paratuberculosis (MAP) ATCC Strain 
19698 were further characterized and compared.   The traditional production method, which 
incorporates autoclaving prior to filtration of the culture media, was compared to a modified 
method that removed autoclaving during the process.  PPD preparations were characterized 
utilizing mass spectrometry and compared for skin test responses using the guinea pig potency 
assay.  Mass spectrometry identified 131 MAP proteins among the three PPD preparations, ten 
which were present in all preparations.  Guinea pig potency testing between PPD preparations 
resulted in significant difference between production lots.  The overall potency of each tested lot 
was acceptable based upon the measured reactivity. Selected proteins identified by mass 
spectrometry were recombinantly expressed and purified from E. coli and evaluated by the 
guinea pig potency assay.  Seven recombinant proteins showed greater erythema as compared to 
the reference PPD lot 9801 in paired guinea pigs and stimulated interferon gamma production 
from Johne’s positive animals.  These results suggest that autoclaving culture suspensions is not 
a necessary step in PPD production and specific proteins could supplant the PPD antigen for the 
intradermal skin test and for use as in-vitro assay reagents.  
Key Words:  bovine, paratuberculosis, proteomics, purified protein derivative, Johne’s disease, 
skin test, delayed-type-hypersensitivity. 
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Introduction 
The use of cell-mediated immunity detection methods remains the optimal tool for 
identifying animals in the early stages of Johne’s disease caused by Mycobacterium avium subsp. 
paratuberculosis (MAP).  Testing protocols utilizing purified protein derivatives (PPD) in either 
intradermal skin testing or interferon-gamma (IFN-γ) assays provide for such detection methods.  
In the early stages of infection the immune response involves a T helper type 1 (Th1) 
polarization of the immune response along with MAP-specific IFN-γ production (Stabel, 2006; 
Stabel and Whitlock, 2001).  As disease progresses, there is a transition to a T helper type 2 
(Th2) immune response with the production of MAP-specific antibodies and a decrease in IFN-γ 
production.  During this transitional stage accurate diagnosis can be difficult and the use of 
multiple testing strategies proves most useful (Koets et al., 2002; Nielsen and Toft, 2008). 
The importance of having a reliable and well characterized PPD as part of an intradermal 
skin testing program or as a mitogen in an IFN-γ assay is critical to providing improved test 
protocols during preclinical stages of infection (Coussens, 2001; Stabel, 1996).  Various studies 
have reported issues related to sensitivity and specificity of PPD preparations when used for such 
test methods (de Lisle and Duncan, 1981; de Lisle et al., 1980; Jungersen et al., 2002; Jungersen 
et al., 2012; Larsen et al., 1963) 
Factors including a consistent production protocol utilizing a well-defined MAP isolate 
can influence protein expression.  Comparison of MAP strain K-10 and a field isolate from a 
cow exhibiting clinical signs of Johne’s disease revealed there were marked differences in 
protein expression when examined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and mass spectrometry (Radosevich et al., 2007).  Differences in protein 
expression were related to differences in passage level of the two isolates compared.  What was 
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not clear from the study is how the specific protein differences may affect MAP virulence or the 
specific role the various proteins play in cell-mediated immune responses. 
Additional information contributed from work with various MAC isolates used for PPD 
production identified a large sequence polymorphism (referred to as LSPjn) as being absent in 
seven such MAP strains (Semret et al., 2006).  Deletion of this particular locus is thought to have 
occurred due to continual laboratory passage as it was shown to be intact in field isolates.  
Mass spectrometry analysis of various PPD products has begun to reveal variations in 
PPD composition.  Proteomic analysis of Mycobacterium bovis (MB), Mycobacterium avium 
subspecies avium (MAA), and MAP derived PPD suspensions was able to identify a large 
number of proteins present in each preparation (Santema et al., 2009).  Three MAP proteins were 
further analyzed in a serum antibody ELISA with MAP1138c being the best recognized.  Poor 
reactivity in a lymphocyte proliferative assay did not support use of the selected proteins as 
being viable for consideration in cell-mediated immune response based assays.  
An analysis of various PPD products from various laboratories and facilities revealed that 
the proteomic composition was highly similar and that variability identified was due to MAP 
strains selected for production protocols as well as the age of the MAP cultures (Wynne et al., 
2012).   The abundance of the various proteins in each PPD preparation varied greatly, which 
may be related to production processes or the specific MAP isolate used.  A critical finding in 
this study was that MAP PPD produced at the United States Department of Agriculture (USDA) 
National Veterinary Services Laboratories (NVSL) contained only six detectable proteins.  This 
result seemed in contrast to protein quantity indicated from previous potency testing results 
against MAP 19698 sensitized guinea pigs in which such testing revealed acceptable potency 
results. 
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In our current work, previously prepared MAP PPD suspensions were selected for 
characterization of the specific protein components.  Characterization was conducted by mass 
spectrometry for initial identification of protein components.  Guinea pig potency testing was 
conducted to compare PPD preparations and to also provide information of cell-mediated 
responses of specific individual proteins identified from the mass spectrometry data.  
Information from this study can be used toward improved production methods for a well 
characterized and consistent PPD.  Such an improved reagent would provide higher confidence 
in the use of cell-mediated immune response test protocols allowing for earlier detection of MAP 
infected animals.    
 
Materials and Methods 
Bacteria, PPD preparation and source.  MAP strain 19698 was used in all the MAP PPD 
production processes.  E. coli DH5-α served as the host strain for recombinant protein 
expression.   PPD lots produced at the NVSL in 1998 (9801), and ten years later in 2008 (0802, 
0803A) were produced by traditional production methods involving autoclaving of production 
flasks containing floating cultures with subsequent protein precipitation using trichloroacetic 
acid (TCA) as described previously (Haagsma and Angus, 1995; Steadham et al., 2002).  Lot 
9801 currently serves as a reference lot and has been used in the field for cattle skin testing 
purposes since its production in 1998.  Lot 0902 was produced by an alternative production 
method involving sterile filtration in place of autoclaving followed by protein precipitation using 
TCA.  Lots 0902A and 0902B, which comprised the larger PPD 0902 bulk preparation, were 
harvested on different days from the same culture inoculum.  In production of large PPD batches 
(lots), multiple concentrated harvest bulks are commonly combined to reduce the number of 
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potency tests conducted and allow for larger final product release volumes.  Due to the 
alternative production process used for PPD 0902 these two smaller bulks were held as reserve 
on each harvest date to evaluate possible differences in this revised procedure.  Purity testing was 
conducted in accordance with the Code of Federal Regulations, 9CFR part 113.26.   
Cattle sera.    Serum samples were obtained from cattle housed at the NVSL and from 
naturally infected animals on dairy farms in the US.  Sera from these animals were used in the 
annual nationwide NVSL Johne’s disease serology proficiency test program, and represent a 
well-characterized and standardized serum set.  Naturally infected cattle were confirmed 
serologically positive on both the Prionics Paracheck® and IDEXX MAP ELISA assays (Table 
1).  Positive cattle were also confirmed positive by fecal culture on Herrold’s Egg Yolk with 
Mycobactin J (HEY-MJ).  Negative sera were from negative control source animals within the 
NVSL and also from MAP negative confirmed production herds participating in the USDA 
Voluntary Bovine Johne’s Disease Control Program.  Negative animals were confirmed by 
bacterial culture and serology using the same diagnostic tests as the positive cattle. 
Recombinant protein production.  The cloning, production, and purification of 
recombinant MAP proteins were performed as previously described (Bannantine and Paustian, 
2006).  Briefly, maltose binding protein (MBP) fusions of MAP predicted coding sequences 
were constructed in Escherichia coli DH5α using the pMAL-c2 vector (New England Biolabs, 
Beverly, MA).  Primers designed from the reading frame of each coding sequence contained an 
XbaI site in the 5’ primer and a HindIII site in the 3’ primer for cloning.  Ligation of the DNA 
fragments was followed by transformation into E. coli and selection on Luria-Bertani (LB) agar 
plates containing 100 µg/ml ampicillin.  PCR screening of ampicillin resistant colonies was 
conducted with primers used to amplify the sequence from MAP DNA.   
67 
 
Each MBP fusion protein was overexpressed in E. coli by induction of 1-L LB broth cultures 
with 0.3 mM isopropyl-β-D-thiogalactopyranoside (IPTG, Sigma Chemical Company, St. Louis, 
MO) for 2.5 hr with shaking at 37oC.  Cells were harvested by centrifugation and resuspended in 
column buffer for sonication.  Affinity chromatography purified protein fractions were eluted 
and analyzed using a NanoDrop spectrophotometer at 280 nm.  The most concentrated fractions 
were pooled and dialyzed at 4oC against 1.5 L phosphate buffered saline (PBS).  Purified 
proteins were aliquoted and stored at -20oC for future use. 
  Mass spectrometry.  Proteomics experiments were accomplished using previously 
published methods (Lippolis et al., 2014).  Total protein concentrations were determined using 
the Biorad Protein Assay Kit (BioRad, Hercules CA), along with a known bovine serum albumin 
(BSA) standard.  Briefly, 100 μg of each sample was resuspended in 250 µl PBS, 3 μl of 10% 
sodium deoxycholate acid, and 1 μl of 2% sodium dodecyl sulfate (SDS).  Samples were heated 
at 90°C for 20 minutes, then cooled on ice for 5 minutes.  Next, 2 μl of 50 mM tris-(2-
carboxyethyl) phosphine and 1.5 μl fresh 1M iodoacetimide were added and the samples were 
incubated 1 hour in the dark at room temperature.  An equal volume of methanol was added to 
the protein sample.  Proteins were then digested using 10 μg of trypsin gold (Promega) and 
incubated overnight at 37°C.  Formic acid (10 μl) was added, the sample vortexed, and then spun 
(14,000 x g for 10 minutes at 4°C) to precipitate detergents.  Supernatants were transferred to 
clean tubes and then dried in a vacuum centrifuge. Peptides were dried in one tube, and held at -
80°C until use. 
Samples were injected onto nano-LC chromatography using a Proxeon Easy-nLC (Thermo 
Fisher Scientific, West Palm Beach, FL) connected to the mass spectrometer.  The 
chromatography used a trapping column (Proxeon Easy-Column, 2 cm, ID 100 μm, 5um, 120A, 
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C18) and an analytical column (Proxeon Easy-Column, 10 cm, ID 75 μm, 3um, 120A, C18).  
The gradient using a mobile phase A (95% H2O: 5% acetonitrile and 0.1% formic acid) and 
mobile phase B (5% H2O: 95% acetonitrile and 0.1% formic acid).  The gradient was: 0% B for 
3 minutes, 0%-8% B from 3-5 minutes, 8-18% B from 5-85 minutes, 18-30% B from 85-100 
minutes, 30-90% B from 100-105 minutes, and held at 90% B from 105-120 minutes at 
continuous flow rate throughout the gradient of 300 nl/min.  
The analytical column was connected to a PicoTip Emitter (New Objectives, Woburn, MA; 
FS360-75-15-N-20) cut to size.  The column and Emitter were attached to a LTQ OrbiTrap 
Velos Pro (Thermo Fisher Scientific, West Palm Beach, FL) mass spectrometer using the 
Proxeon Nanospray Flex Ion Source.  The capillary temperature was set at 275°C and spray 
voltage was 2.8 kV.  The mass spectrometer used a data dependent method.  In MS mode the 
instrument was set to scan 300-2000 m/z with a resolution of 30,000 FWHM.  A minimal signal 
of 20,000 could trigger MSMS and 10 consecutive MSMS were possible.  The activation type 
used was HCD.  The normalized collision energy was set to 35 and repeat mass exclusion was 
set to 120 seconds.  
Tandem mass spectra were extracted and charge state deconvoluted by Proteome Discoverer 
version 1.4.0.288 (Thermo Fisher Scientific, San Jose, CA, USA; version 1.3.0.339).  All 
MS/MS samples were analyzed using Sequest assuming digestion with trypsin.  Sequest was set 
up to search a combined FASTA database of Mycobacterium avium complex (taxon #120793) 
and Mycobacterium tuberculosis complex (taxon #77643) databases generated in July of 2013.  
Sequest was searched with a fragment ion mass tolerance of 0.800 Da and a parent ion tolerance 
of 10.0 PPM. 
Database searching.  Tandem mass spectra were extracted and charge state deconvoluted by 
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Proteome Discoverer version 1.4.0.288 (Thermo Fisher Scientific, San Jose, CA, USA; version 
1.3.0.339).  All MS/MS samples were analyzed using Sequest assuming digestion with trypsin.  
Sequest was set up to search a combined FASTA database of Mycobacterium avium complex 
(taxon #120793) and Mycobacterium tuberculosis complex (taxon #77643) databases generated 
in July of 2013. Sequest was searched with a fragment ion mass tolerance of 0.800 Da and a 
parent ion tolerance of 10.0 PPM. 
Guinea pig potency assay.  Conventional guinea pigs weighing between 450 and 600 grams 
were obtained and acclimated to the vivarium housing conditions prior to testing.  Guinea pigs 
were sensitized utilizing a Johne’s bacterin preparation (NVSL lot #0601) consisting of heat-
killed MAP cells homogenized in light mineral oil.  The bacterin consisted of 23 grams of cells 
homogenized in 180 ml of mineral oil.   
The Johne’s bacterin was diluted 1:4.55 in mineral oil and held at 45oC on a hotplate.  Each 
guinea pig was inoculated intramuscularly with 0.1 ml of the warmed suspension.  Control 
guinea pigs were inoculated intramuscularly with 0.1 ml of phosphate chloride buffer (34 mM 
Na2HPO4, 86 mM NaCl).  The sensitization period after inoculation was 35 days after which 
PPD lot numbers 9801, 0802, 0803A, 0902A were prepared for animal inoculation.  Each 
preparation was diluted to 10 µg/ml and 2 µg/ml in phosphate chloride buffer.  Diluted PPD 
suspensions were bottled and labeled as sample A, sample B, sample C, and sample D.  
After the sensitization period and prior to inoculation, all guinea pigs had both sides 
shaved in preparation for inoculations.  The shaved areas were divided into two equal blocks. 
Each block contained four randomized injection sites resulting in eight total injections. This 
resulted in replicate injections of each PPD for each guinea pig.  Guinea pigs were injected 
intradermally with a volume of 0.1 ml of the designated MAP PPDs 
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Twelve guinea pigs (6 guinea pigs for each PPD concentration) were used for PPD 
inoculation.  An additional 4 guinea pigs were used as negative non-sensitized controls.  Twenty-
four hours post-injection, test responses were measured to the closest square millimeter by 
measuring the greater and lesser dimensions of the erythema.   
All animal work was conducted under the NVSL approved Institutional Animal Care and 
Use Committee protocols. 
Guinea pig potency assay of individual proteins.  Forty-seven MAP proteins identified by 
mass spectrometry were recombinantly expressed in E. coli for further evaluation in the guinea 
pig potency assay.  Eighteen guinea pigs, sensitized as described previously, were used in the 
screening of selected proteins.   
After the 35-day sensitization period and prior to inoculation, all 16 guinea pigs had both 
sides shaved.   There was a single row of four randomized injection sites blocked on each side of 
each animal.  This arrangement allowed for the injection of 6 proteins and two control proteins in 
each animal.  Seven pairs of guinea pigs each received six proteins (42 proteins total) and the 
final pair of animals received five proteins.  One guinea pig in each pair also received either PPD 
9801 or PPD 0902, whereas the second guinea pig received the MBP/LacZ control peptide 
diluted to 10 µg/ml in phosphate chloride buffer.  This configuration enabled each of the 47 
recombinant proteins to be injected twice.  Guinea pigs were injected intradermally with a 
volume of 0.1 ml of the designated antigen. 
Twelve recombinant proteins were evaluated further in a second guinea pig potency test.  
Thirty guinea pigs were sensitized as previously described and four guinea pigs served as non-
sensitized control animals.  Recombinant proteins were randomized and assigned to respective 
guinea pig groupings.  PPD 9801 served as a positive control and phosphate chloride buffer 
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served as a negative control.  Suspensions were randomized utilizing a Microsoft Excel 
randomization program.  Sensitized guinea pigs were assigned to four groups of five animals per 
group.   
After the sensitization period and prior to inoculation, all guinea pigs had both sides shaved.   
Each side contained four randomized injection sites resulting in eight total injections for each 
animal.  Each sensitized animal received replicate inoculations of two recombinant proteins 
divided between the left and right sides.  Each animal also received one inoculation of lot 9801 
and one inoculation of phosphate chloride buffer.  Paired non-sensitized control animals received 
one inoculation of designated recombinant proteins as well as control suspensions.  Guinea pigs 
were injected intradermally with a 0.1 ml of the designated MAP recombinant protein or control 
suspension.  Guinea pigs were housed with 5 animals per cage with each of the five animals from 
different treatment groups within a cage.  Test responses were again measured to the closest 
square millimeter 24 hours post-injection.  Recombinant proteins were compared against the 
positive control within each animal. 
Gamma-interferon testing using recombinant proteins.  Evaluation of recombinant MAP 
proteins was conducted using six Johne’s positive cattle, two M. bovis sensitized cattle, and four 
non-infected control cattle. Approximately 40 - 50 ml of blood was collected from each animal 
into vacutainer blood tubes containing sodium heparin.  Blood samples were held at room 
temperature prior to stimulation. 
Six to seven hours after collection blood tubes for each individual animal were mixed well 
and combined into a sterile 50 ml conical tube.  For each animal 1.5 ml aliquots of blood were 
dispensed into each well of a 24-well tissue culture plate.  Blood was cultured alone as non-
stimulated controls, or with pokeweed mitogen at a concentration of 10 µg/ml to serve as a 
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control providing information related to the viability of cells within each sample.  Whole blood 
was also cultured with designated mitogens at 10 µg/ml.  Mitogens used for evaluation were as 
follows:  MAP PPD 9801 (PPD-J), M. bovis PPD (PPD-B), M. avium PPD (PPD-A), 
MAP_1997, MAP_4143, MAP_1138c, MAP_3567, MAP_3061c, MAP_2121c, and 
MAP_3651c.  For all mitogens, 100 µl was dispensed into each designated well and each 
mitogen was cultured in duplicate wells. 
Plates were covered and incubated at 37oC for 21-22 hours.  Plates were centrifuged at 500 
x g for 15 minutes and the plasma from each well was harvested and refrigerated.  Plasma 
samples were tested over the next 72 hours. 
The INF-γ ELISA was conducted according to the manufacturer’s directions (Prionics - 
BOVIGAM®).  Samples from each well were incubated in duplicate for one hour at room 
temperature in a 96-well plate that is pre-coated with anti-bovine INF-γ antibody.  Plates were 
washed six times with wash solution and then incubated with an anti-bovine INF-γ-horseradish 
peroxidase conjugate for 30 minutes at room temperature.  Plates were then washed six times 
with wash solution and incubated with peroxidase substrate for 30 minutes at room temperature.  
Enzyme stopping solution was added to each well and the plates were read at A450 and A650 nm. 
Statistical analysis.  The PPD mean skin test responses from the guinea pig potency test were 
compared by ANOVA.  Differences were considered statistically significant at a P of < 0.05. 
Results for the recombinant protein guinea pig potency testing were evaluated by 
calculating the treatment group mean erythema value using the measurements for each individual 
animal comprising the treatment group.  Paired comparisons calculating the difference between 
the response of the treatment to the response of the positive control for each animal were 
completed.  Results from the five injections for each respective protein were then averaged and 
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ranked based on the average differences.  A positive difference indicates the average response 
from the treatment is higher than the average response from the positive control.  For this 
difference data, a 95% confidence interval was calculated for each treatment group. 
 
Results 
PPD potency assay in guinea pigs.  Potency testing of the traditional and alternate PPD 
production lots resulted in significant differences (P < 0.05) when compared against the 
reference standard (lot 9801; Table 2).  Traditional lot 0803A and alternate lot 0902 resulted in 
the greatest skin test responses and all responses showed a larger erythema as PPD concentration 
increased.  The average area of the erythema at the injection sites for lot numbers 0803A and 
0902 were much greater than the average area for the reference standard (261% and 177%, 
respectively,).  Traditional PPD lot 0802 resulted in a measurement that was 79% of the average 
area compared to the reference standard.  An acceptable potency test result for new production 
lots must have a response that is a minimum of 75% compared to the reference response.  Using 
these criteria, all three PPD lots demonstrated acceptable potency, although 0802 is marginal.  
These data suggest that the potency was not adversely affected by removal of the autoclave step.  
Analysis of PPD preparations by mass spectrometry.  Mass spectrometry analysis was 
performed on three PPDs, including the reference (9801) and alternative lots (902A and 902B).  
The total number of proteins identified among all three PPDs was 194, 78% of which were 
unique to an individual PPD (Figure 1).  All 194 proteins, including peptide matches and 
molecular weights are listed in Table S1.  Ten proteins were detected in all three PPD 
suspensions (Figure 2).  These 10 proteins may represent the best candidates for development of 
a consistent recombinant PPD and are listed at the top of Table S1.  MAP_3840 had the greatest 
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number of peptide matches among all the PPDs, and was also one of the most common proteins 
observed among PPDs analyzed in the Wynne et al., 2012 and Santema et al., 2009 studies.  
Furthermore, it was identified as a cell surface protein using a trypsin shaving technique (He and 
De Buck, 2010).  These results suggest that MAP_3840, which encodes a 70-kDa heat shock 
protein, is present in high abundance in MAP.  Also present among all PPDs were MAP_1588c 
and MAP_1589c, which are tandemly located on the K-10 genome (Li et al., 2005) and have 
been examined as potential diagnostic antigens long ago (Olsen et al., 2001).  Furthermore, both 
have been reported as a stress protein (Gumber et al., 2009) and MAP_1589c was also found to 
be surface located (He and De Buck, 2010).   
Potency assay of recombinant proteins in guinea pigs.  Forty-seven of the 194 proteins 
identified by mass spectrometry were cloned, expressed, and purified in E. coli.  These 
recombinant proteins were used for potency testing to determine if they substantially contribute 
to the skin test response observed with PPDs.  Seven proteins showed reproducible skin test 
responses that were stronger than or equivalent to the reference lot 9801 (Table 3, highlighted in 
bold).  The strongest skin test response among all recombinant proteins was elicited by 
MAP_1997, which is annotated as an acyl-carrier protein (Table 3).  This protein has not been 
previously described as an antigen in the literature, although it was listed among surface exposed 
proteins in MAP (He and De Buck, 2010).  Known antigens that are among these seven proteins 
include the major membrane protein (Bannantine et al., 2007; Li et al., 2007) and the LrpG 
protein (Leite et al., 2014; Santema et al., 2009).  Seventeen additional proteins produced 
measureable skin test response in one of two replicate intradermal inoculations.  The MBP/Lac-Z 
control suspension showed no visible reactivity at any inoculation site. 
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Twelve recombinant proteins that showed the largest skin test responses listed in Table 3 
were evaluated further in a second guinea pig potency test.  Even the four best proteins were still 
not considered significantly different from the reference 9801 PPD based upon results from the 
ranking by difference calculations (Table 4).  Those recombinant proteins were MAP_1997, 
MAP_4143, MAP_3567, and MAP_1138c.  The only recombinant protein that elicited responses 
greater than the reference PPD was MAP_1997, but this difference was not significant.  The 
eight recombinant proteins showing the greatest responses are shown in Figure 3.  MAP_3061c, 
MAP_3651c, and MAP_2121c elicited responses significantly less than the reference PPD. 
Gamma-interferon assay using MAP recombinant proteins.  Seven recombinant proteins 
having the best performance in the guinea pig potency test were further evaluated as mitogens in 
an IFN-γ stimulation assay.  The proteins were evaluated against Johne’s positive animals (#790, 
#2407, #2222, #8339, #1211, and #1044) based upon results of serological and fecal shedding, 
M. bovis sensitized animals (#4 and #11), and negative control animals (#1081, #212, #61, and 
#1392).  MAP_3651c and MAP_3567 demonstrated the greatest IFN-γ stimulation within the 
Johne’s positive animals with responses in some animals being greater than the stimulation 
values from MAP PPD 9801 (Figure 4).  MAP_1997, which resulted in the greatest skin test 
response in the guinea pig potency test, showed the least IFN-γ stimulation.  Each MAP 
recombinant protein resulted in negative stimulation values against samples from the M. bovis 
sensitized animals (Figure 5).  All negative control samples remained negative for IFN-γ 
stimulation using MAP recombinant proteins or PPD suspensions, indicating good specificity. 
In summary, selected recombinant proteins provided comparable or more potent responses than 
the PPD in skin testing procedures, as determined by the guinea pig potency assay.  In addition, 
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these recombinant proteins may serve as antigens in an INF-γ assay, resulting in interferon-
gamma production comparable or greater than stimulation using MAP PPD. 
 
Discussion 
This study had two objectives with the overall goal of analyzing an antigen with 
previously limited evaluation, but of importance for use in Johne’s disease diagnosis and 
research.  One objective was to compare the effect of autoclaving on MAP PPD preparations and 
measure this effect through guinea pig potency testing.  The data suggest that removal of the 
autoclaving step may enhance immunogenicity and prevent protein degradation, but does not 
negatively affect the potency.  A second objective was to define the components present in each 
preparation through a proteomic analysis and determine proteins commonly present in the 
different production lots.  A subset of the identified PPD proteins was then selected for 
evaluation in a guinea pig potency test to determine skin test responsiveness in sensitized 
animals.  In addition these proteins were further evaluated to determine their use as mitogens in 
IFN-γ testing.  These objectives worked toward the overall goal of obtaining a more consistent 
and equally potent PPD that may be composed entirely of recombinant proteins.  This reagent 
could then circumvent the problems inherent in obtaining consistently potent PPDs.  Finally, a 
“recombinant PPD” may avoid cross reactivity issues in cattle vaccinated against M. bovis or 
MAP. 
The use of high pressure heat inherent in the autoclaving process results in lysis and the 
appearance of cytosolic proteins that may not be present when autoclaving is eliminated.  The 
presence of the 70-kDa heat shock protein (MAP_3840) in both traditional and alternate PPDs 
argues against this idea since it is considered a cytosolic protein.  However, because this protein 
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is present in high abundance in MAP, it appears at some level in all bacterial fractions including 
membrane and secreted fractions (Facciuolo et al., 2013; He and De Buck, 2010).  Since secreted 
or surface proteins should be the first antigenic components encountered in an infected animal, 
this may allow for more specific responses as well as possibly earlier detection.   Multiple 
studies have shown that many strong antigens are also secreted proteins in MAP (Cho and 
Collins, 2006; Willemsen et al., 2006).  The interest in secreted antigens has primarily involved 
their significance for use in enzyme-linked immunosorbent assays (Facciuolo et al., 2013; Shin 
et al., 2008).  In addition, the 10 proteins identified by mass spectrometry common to all three 
NVSL PPD preparations were also identified as part of the culture filtrate protein composition 
characterized by Facciuolo et al (2013).  In total there were 58 proteins in the NVSL PPD 
preparations identified by mass spectrometry that were in common with the Facciuolo et al. 
study.  Furthermore, of the seven recombinant proteins resulting in the greatest skin erythema in 
the guinea pig potency test five of those proteins were also identified in the culture filtrate found 
by Facciuolo et al. (2013).  These include MAP_1997, MAP_4143, and MAP_3061c, which 
were the most reactive in the guinea pig potency test. 
Potency testing of four MAP PPD lots (9801, 0802, 08032A and 0902) was conducted to 
ensure that the PPD’s produced by conventional and a modified production protocol retained 
acceptable potency in sensitized guinea pigs.  Replacing the autoclaving step with a sterile 
filtration process to remove cells would avoid protein degradation, but it was uncertain if this 
change may affect potency.   Results from potency testing suggest there was no significant effect 
on potency regardless of whether the culture material was subjected to autoclaving or sterile 
filtration.  These results represent the first study to examine this variable effect of heating on 
PPD performance in guinea pig potency testing.  However, our results suggest that age of the 
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PPDs might have an effect on potency because the skin test responses were greater in the 
recently prepared PPDs (0803A and 0902) than the reference lot prepared in 1998. 
  Work to identify protein components of NVSL MAP PPD lot 9801 utilizing an 
Escherichia coli expression vector system resulted in limited success.  The expression library 
screening procedure, using rabbit antiserum raised against MAP PPD 9801, identified three 
partial protein sequences for MAP0805c, MAP0806c, MAP0807c, and MAP2117c.  The low 
number of proteins identified utilizing the expression library was surprising.  Subsequent 
attempts to amplify these nucleotide sequences were unsuccessful leading to pursuing mass 
spectrometry for identification of individual protein components of the MAP PPD preparations. 
Mass spectrometry analysis of PPD preps has revealed some of the proteins present in 
these complex mixtures of proteins, carbohydrates and lipids.  In a separate study, proteomic 
analysis of M. bovis, M. avium subspecies avium, and MAP derived PPD suspensions identified 
156 proteins among all PPDs (Santema et al., 2009).  Three of these proteins (MAP_1718c, 
MAP_3515c, and MAP_1138c) were further analyzed in a serum antibody ELISA with 
MAP1138c (LprG) emerging as the strongest antigen in high fecal shedding cattle.  MAP LprG 
was also previously identified from a MAP gene fusion library screening study and found to be 
immunogenic in bovine paratuberculosis serum samples by Western blot analysis (Dupont, 
2005).  Our study also identified LprG and it was among the strongest stimulators in guinea pigs 
(Table 3).  However, LprG showed no significant reactivity in a lymphocyte proliferative assay 
(Santema et al., 2009) decreasing its consideration for use in cell-mediated immune response 
based assays.  LprG elicited IFN-γ responses in eight of nine sheep that had been vaccinated with 
an attenuated MAP strain in the study by Dupont et al. (2005).   Using LprG as a mitogen in the 
IFN-γ assay 50% of Johne’s positive cows, and all M. bovis sensitized and MAP negative 
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animals were identified correctly, whereas in the Santema et al. (2009) study there was no 
significant difference between positive and negative animals.  While results varied for use as a 
mitogen for in-vitro IFN-γ stimulation, its ability to elicit immunological responses in both 
humoral and cell-mediated assays may be indicative that MAP LprG is a highly expressed 
protein during all stages of Johne’s disease and could prove to be a more versatile candidate for 
diagnostic assay improvements.  
A total of 194 proteins were identified among all preparations with 110 of these identified 
in lot 9801.  This information greatly adds to a previous study which identified only six proteins 
in this same NVSL lot 9801 (Wynne et al., 2012). It is interesting to note that reference PPD 
9801 had the most proteins identified by LC-MS/MS, yet was migrating as a smear in denaturing 
protein gels and did not appear immunogenic by Western blot analysis or as potent by guinea pig 
sensitization.  These results show that while immune stimulating components were destroyed in 
the heating process, they did not affect characteristics used for MS detection.  Fewer proteins 
were identified in the alternate PPD lots, with 67 and 74 proteins being identified in each 
production lot.  Although a number of proteins were identified in two of the three preparations 
analyzed, only ten proteins were detected in all three preparations.  Combining the results from 
the Wynne et al. (2012) and Santema et al. (2009) studies shows the number of proteins 
consistently appearing in PPD preparations among all three studies is three.  They include 
MAP_4143, MAP_1595, and MAP_3840.  The total number of MAP proteins identified at least 
once in any of the three studies was 214, which suggests a starting point for the complete PPD 
proteome of MAP.  Although some variability may be attributed to the methodology used for 
protein identification, the small overlap of proteins nonetheless further suggests the 
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inconsistencies that can be encountered in PPD production processes and the need to improve 
such processes to reduce or eliminate such variability. 
A subset of proteins identified from mass spectrometry data was evaluated in a well-
established guinea pig potency assay.  During the potency testing a Mbp/Lac-Z control was 
included to ensure this particular component of the recombinant protein composition would not 
accentuate the skin test reactions.  Previous work using Mbp/Lac-Z recombinant MAP proteins 
in a serological assay examined the possible immunological effects of cleaving the Mbp portion 
from the protein structure (Gurung et al., 2013).  Using serum from MAP-infected sheep Gurung 
found that cleaving the Mpb/Lac-Z portion of the proteins had little effect upon the 
immunological reactivity of the proteins.   Reactivity observed in two Mpb/Lac-Z inoculation 
sites during the guinea pig potency testing was likely due to nearby individual protein reactions.  
In both instances the Mpb/Lax-Z inoculation sites were adjacent to inoculation sites of individual 
proteins which had large diffuse intradermal reactions.  Seven proteins, including an acyl carrier 
protein, elongation factor protein, flavoprotein, and a hypothetical protein are among those that 
showed equivalent or greater skin erythema than lot 9801.  Neither Mpb/Lac-Z nor the phosphate 
chloride buffer inoculate sites had measureable reactions during retests of those materials.  These 
data clearly suggest that recombinant proteins are worthy of additional study and could 
ultimately replace the use of PPD preparations for skin testing. 
Antigenicity evaluation in a serological based assay of four individual MAP proteins was 
recently conducted in a study with final results indicating assay performance that was similar to 
currently available commercial assays (Gurung et al., 2014b).  Two proteins, MAP3567 and 
MAP2698c, evaluated in that study were also part of the protein subset screened in the guinea 
pig potency test as part of this study.  MAP3567 induced strong skin test reactions in sensitized 
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guinea pigs while MAP2698c had reactivity lower than either of the PPD suspensions used as 
controls, but still had easily measureable cell-mediated immune responses.  These results are 
similar to additional studies conducted by Gurung (Gurung et al., 2014a; Gurung et al., 2014c) in 
which those studies identified MAP2698c as a strong candidate for additional work related to 
either vaccine formulations or use in an IFN-γ assay.  One contrasting difference found in this 
current study is that MAP3567 appeared to offer better cell mediated immunoreactivity and 
might be a better candidate toward use in a cell-mediated immune detection assay.    
Santema and colleagues used MAP1138c (LprG protein) in a lymphocyte stimulation 
assay and enzyme linked immunosorbent assay resulting in high shedder animals having 
significantly higher responses than negative control animals (Santema et al., 2009).  MAP LprG 
was also previously identified from a MAP gene fusion library screening study and found to be 
immunogenic in bovine paratuberculosis serum samples (Dupont, 2005).  Results from these 
studies correlate well to the finding that MAP LprG was highly immunogenic during the guinea 
pig potency test screening process in this study.  LprG was one of the seven highly reactive 
proteins identified.  A surprising finding from these previous studies is that MAP LprG was 
immunogenic in assays based upon humoral immune responses and cell-mediated immune 
responses since the immune response tends to shift away from a cell-mediated immune response 
during clinical stages of disease.  However, variation and lack of uniformity in the progression of 
antibody response to various antigens during Johne’s disease progression was identified in a 
study by Koets (Koets et al., 2001).  This may be indicative that MAP LprG is highly expressed 
protein during all stages of Johne’s disease and could prove to be a more versatile candidate for 
assay improvements.  
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MAP_0217 and MAP_1609c that were identified by mass spectrometry in PPD lot 
#0902B and PPD lot #9801, respectively, were also used in a previous study evaluating a 
recombinant multiantigenic MAP subunit vaccine (Thakur et al., 2013).  Results of this 
vaccination study indicated that both proteins did not produce significant cell-mediated immune 
responses in vaccinated cattle.  This correlates to the results observed in the present study during 
the guinea pig potency test in which the skin test response elicited by MAP_1609c was 
significantly lower than the control PPD lot 9801. 
MAP recombinant proteins used as antigens in an INF-γ assay showed five proteins as 
potential candidate antigens.  MAP_3651c and MAP_3567 were the strongest mitogens with 
Johne’s positive samples and they correctly identified four of the six animals as positive.  
MAP_3061c, MAP_1138c, and MAP_4143 were comparable to each other, and also identified 
three of the same animals identified by MAP_3651c and MAP_3567.  These results were 
comparable to animals identified as positive using MAP PPD 9801 with differences noted for 
two animals.  Cow #2407 was identified as positive by MAP PPD 9801, but was negative by all 
individual proteins.  In contrast, cow #8339 was negative using MAP 9801, but was positive by 
five of the seven individual proteins.     These results were in contrast to the guinea pig potency 
test results in which MAP_3651c and MAP_3061c did not stimulate skin test responses 
comparable to MAP PPD 9801.  Also in contrast to the strong skin test response in the guinea 
pig potency test, MAP_1997 was not a strong mitogen in the INF-γ stimulation assay.  These 
contrasting differences between the two tests demonstrate that neither test is a good predictor of 
success in the other and may be due to the additional immunological responses ongoing at skin 
test sites that involve more than INF-γ alone. 
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Our results suggest that autoclaving during PPD preparation, though performed for 
decades, is an unnecessary step in PPD production.  Over 100 proteins have now been identified 
from NVSL PPDs that have been used in field studies for decades.  Results from this study have 
also identified a number of proteins that are reactive to skin testing in sensitized guinea pigs and 
as mitogens in IFN-γ assays.  These proteins can contribute to improvements for a well-defined, 
consistent PPD for diagnostic purposes.  Further research is needed to confirm the DTH 
responses of these proteins and examine specificity characteristics to differentiate MAP 
immunological responses from M. bovis-infected cattle.  
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Figure 4  Secretion of IFN-γ using whole blood from Johne’s positive animals.  Absorbance was 
measured at 450 nm. 
 
Figure 5:  Secretion of IFN-γ using whole blood from Mycobacterium bovis sensitized animals 
and negative animals.  Absorbance was measured at 450 nm. 
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Table S1:  Proteins identified by mass spectrometry from Mycobacterium 
avium subsp. paratuberculosis (MAP) PPD lot numbers 9801, 0902A and 
0902B.   Proteins are arranged according to similarity between the various 
PPD suspensions. 
 Number of Peptides 
Additional MAP 
information 
Accession 
MW 
(kDa) 
Locus 
Tag 
0902A 9801 0902B 
MAP 3840 Q00488 67 3840 106 16 148 
hypothetical protein 
MAP1540 
A0QGN6 17 1540 8 18 60 
hypothetical protein 
MAP1589c 
F7PEC2 22 1589c 29 5 29 
BfrA [Mycobacterium 
avium subsp. 
paratuberculosis K-10] 
P45430 18 1595 10 18 24 
elongation factor Tu A0QL35 44 4143 33 18 4 
Alkyl hydroperoxide 
reductase AhpD 
Q73ZL4 19 1588c 10 4 29 
hypothetical protein A0QKI4 19 3428c 7 4 18 
MAP2435c 
hypothetical protein 
A0QCZ3 31 2435c 2 4 6 
pks13 hypothetical 
protein 
A0Q9C4 193 0220 4 4 4 
lpqE hypothetical 
protein 
A0QAB1 19 0474c 2 8 3 
acyl carrier protein 
[Mycobacterium avium 
subsp. paratuberculosis 
K-10] 
A0QER4 13 1997 33 17  
molecular chaperone 
GroEL 
P42384 57 3936 20 29  
hypothetical protein 
MAP2121c 
A0QED3 34 2121c 11 7  
molecular chaperone 
GroES 
A0QKR3 11 4264 9 8  
F0F1 ATP synthase 
subunit alpha 
A0QCX6 60 2453c 2 13  
aceAb isocitrate 
lyase 
A0QGD1 85 1643 6 2  
pgk phosphoglycerate 
kinase 
A0QHY4 42 1165 10 2  
sahH S-adenosyl-L-
homocysteine 
hydrolase 
Q73UK6 54 3362c 14 2  
gap glyceraldehyde-3-
phosphate 
dehydrogenase 
P94915 36 1164 4 8  
desA2 DesA2 F7PAY8 31 2698c 10 2  
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 Table S1 continued 
polynucleotide 
phosphorylase/polyade
nylase 
A0QIW5 80 2891c 7 2  
hypothetical protein F7PBR8 30 0494 5 2  
nusG, transcription 
antitermination protein 
NusG 
A0PM06 26 4111 3 3  
groEL, molecular 
chaperone GroEL 
A0QKR2 56 4265 2 4  
LprG A0QI11 26 1138c 7  32 
FKBP-type peptidyl-
prolyl cis-trans 
isomerase 
F7PEP6 16 1693c 7  32 
fructose-1,6-
bisphosphate aldolase 
A0QN95 32 4308c 7  32 
hypothetical protein Q73UG6 33 3402 10  17 
hypothetical protein A0QGB4 23 1659 3  17 
hypothetical protein A0QIE1 12 2723c 3  14 
ClpB Q73T66 93 3853 3  6 
glcB malate synthase G Q73ZQ2 80 1549c 5  2 
Protein of unknown 
function (DUF2782) 
A0QLN4 14 
DUF278
2 
 4 35 
DevB F7PCY3 26 1174c  3 15 
hypothetical protein 
MAP3872 
A0QLW3 16 3872  3 13 
elongation factor Ts P61336 29 2955c  4 11 
adk adenylate kinase F7P5P8 20 4199  2 3 
trpC - indole-3-
glycerol-phosphate 
synthase 
A0QHH0 28 1305  2 3 
Wag31 A0QF61 27 1889c 14   
FadE3_2 A0QME1 42 3651c 14   
heat shock protein 
GrpE 
A0QLZ5 24 3841 13   
hypothetical protein F7P1T5 55 0023c 6   
thiol peroxidase A0QGC1 17 1653 11   
type II citrate synthase 
- gltA 
F7P431 48 0829 3   
hypothetical protein A0QMX5 30 3567 6   
hypothetical protein A0QAP1 15 0593c 8   
pepD hypothetical 
protein 
F7PCA9 95 2287 4   
hypothetical protein A0PPW0 28 3061c 4   
fbpC2 A0QN12 38 3531c 3   
hypothetical protein A0QC92 26 2637c 4   
prcB A0QFB5 31 1835c 4   
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Table S1 continued 
hypothetical protein A0QJ99 30 3007 5   
gyrA - DNA gyrase 
subunit A 
A0Q8S1 92 0006 2   
alanyl-tRNA 
synthetase 
A0QI75 97  2   
moxR A0QHU3 42 1205 3   
hypothetical protein B1A036 22 0187c 3   
hypothetical protein A0QDD7 179 2294c 2   
3-ketoacyl-ACP 
reductase 
F7P791 47 3692c 2   
phosphoserine 
aminotransferase 
Q742L2 40 0823c 2   
birA biotin-protein 
ligase 
A0QKF1 27 3397c 2   
FadE25_2 A0QPV4 44 0150c 3   
succinic semialdehyde 
dehydrogenase 
A0QMB9 50 3673c 3   
AldB F7P8J8 53 3413 3   
hypothetical protein Q745E8 17 0151c 3   
hypothetical protein A0QIY0 33 2905c 2   
hypothetical protein A0QK49 47 3293 2   
hypothetical protein 
MAP3193 
UPI0001B
59C72 
43 3193  25  
hypothetical protein A0QHD3 14 1339  7  
ATP synthase, F1 beta 
subunit 
A0QCX8 53 ----  8  
hypothetical protein A0QME0 36 3652  7  
hypothetical protein A0QJU0 30 3194  7  
fixB hypothetical 
protein 
A0QJE9 31 3060c  6  
D-3-phosphoglycerate 
dehydrogenase 
A0QJC3 54 3033c  4  
hypothetical protein A0QJU5 19 3199  4  
fas A0QD96 328 2332c  3  
cysK hypothetical 
protein 
A0QED1 34 2123  3  
hypothetical protein A0Q9Z7 25 0398c  4  
hupB A0QJB5 22 3024c  3  
hypothetical protein A0QJU3 36 3197  4  
heat shock protein 90 A0QEJ0 73 2069c  2  
htrA hypothetical 
protein 
A0QCH2 52 2555c  2  
2-oxoglutarate 
ferredoxin 
oxidoreductase subunit 
beta 
A0QDF7 39 2276c  2  
hypothetical protein 
MAP 2432c 
A0QCZ5 96 2432c  2  
hypothetical protein A0QGJ0 50 1587c  2  
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Table S1 continued 
fbpB Q06947 35 1609c 3 3  
hypothetical protein A0QCC7 221 2603c  2  
hypothetical protein A0QCH0 23 2558  2  
hypothetical protein A0QFK9 37 1743c  2  
NADH deyhdrogenase 
subunit G 
A0QJV3 84 3207  2  
hypothetical protein A0QNC0 126 4336  2  
fumC - fumarate 
hydratase 
F7PAZ3 50 2693  2  
hypothetical protein Q73XM1 16 2288c  3  
KatG A0QGA4 82 1668c  2  
pterin-4-alpha-
carbinolamine 
dehydratase 
P61733 10 2623   23 
hypothetical protein A0QBF9 11 0796c   19 
putative epimerase, 
PhzC/PhzF 
F7PAJ3 24 8450   12 
lppZ hypothetical 
protein 
A0QJD0 37 3041   15 
cyanate hydratase A0QL81 17 4098   12 
fbpC1 FbpC1 A0Q9C1 31 0217   11 
MAP3554c methionine 
sulfoxide reductase A 
A0QMY8 18 3554c   10 
deoxyuridine 5'-
triphosphate 
nucleotidohydrolase 
A0QIM8 16 2814c   8 
hypothetical protein A0QAA8 28 0471   8 
hypothetical protein Q73VM1 15 2992c   10 
folK - hypothetical 
protein 
A0QA88 19 0452   6 
hypothetical protein A0QKD9 32 3385   7 
hypothetical protein A0Q9Q8 14 0343   9 
lprC hypothetical 
protein 
A0PUQ0 20 2497c   10 
PhoS2_2 A0QBL4 37 0872   9 
MAP 1706 
hypothetical protein 
A0QG62 13 1706   8 
PpiA A0PKC2 19 0011   2 
pknB hypothetical 
protein 
A0Q8T1 66 0016c   5 
hypothetical protein A0Q8W6 37 0047c   6 
acylphosphatase A0QJ63 11 2991c   5 
ribosome binding 
factor 
A0QIY1 17 2906c   4 
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Table S1 continued 
hypothetical protein A0QKI9 48 3433   5 
lactoylglutathione 
lyase-like lyase 
A0QCP4 15 ----   3 
phosphoribosylaminoi
midazole carboxylase 
catalytic subunit 
A0QKE7 18 3393c   3 
ndk - nucleoside 
diphosphate kinase 
A0QDG6 15 2268c   4 
hypothetical protein A0QKY3 24 4196   2 
hypothetical protein A0QC28 34 2694   4 
hypothetical protein F7P241 18 1885c   2 
hypothetical protein A1UGX2 18 1542   2 
hypothetical protein Q73YD6 27 2020   2 
hypothetical protein A0QBU5 60 0948   3 
hypothetical protein A0QCP3 14 2482   3 
hypothetical protein A0Q902 16 0083c   2 
hypothetical protein A0QC51 14 2677c   2 
hypothetical protein A0QKU1 29 4237c   2 
hypothetical protein A0QLV9 21 3875c   2 
hypothetical protein A0QCP9 23 2477c   2 
hypothetical protein A0QMB5 14 3678   2 
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Table 1:  Cattle Sera used for IFN-γ stimulation assay 
Animal ID Serological 
Statusa 
IDEXX 
ELISA Value 
Prionics 
ELISA Value 
Fecal Culture 
Statusb 
790 Neg 0.189 N/A Neg 
2407 Neg 0.260 N/A Neg 
2222 Pos 2.320 N/A Moderate 
8339 Pos 1.930 N/A Low 
1211 Neg 0.036 N/A Neg 
1044 Neg 0.079 N/A Neg 
4 Negd N/A N/A Neg 
11 Negd N/A N/A Neg 
1081 Neg 0.036 N/A Neg 
212 Neg 0.067 N/A Neg 
61 Negd N/A N/A Neg 
  1392 Negd N/A N/A Neg 
a Serological status determined by IDEXX and Prionics ELLISA test results. 
b  1-10 CFU/gr feces = low shedder; 11-50 CFU/gr feces = moderate shedder;  >50 CFU/gram of feces = high 
shedder 
c Serum samples used in IFN-γ testing only. 
d Based upon previous IFN-γ testing. 
 
 
 
 
Table 2:  Guinea pig potency test skin test responses at 24 hours post-inoculation of Mycobacterium 
avium subsp. paratuberculosis (MAP) purified protein derivative (PPD). 
PPD 
Concentration 
PPD 9801 PPD 0802 PPD 0803A PPD 0902 
10 µg/ml 143.22 + 48.82 93.63 + 15.59 264.25 + 39.72 202.07 + 39.63 
2 µg/ml 45.52 + 32.13a 53.45 + 15.49 228.41 + 41.91 132.50 + 67.79 
a PPD 9801, 2 µg/ml sample data, contained one inoculation of one guinea pig which had not measureable 
skin reaction.  This resulted in an elevated standard deviation value.  All guinea pigs were sensitized with 
MAP strain 19698 killed cells.  Values represent the average response (mm2 + standard deviation) of six 
guinea pigs used for evaluating each PPD concentration. 
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Table 3:  Positive skin test responses in a guinea pig potency test of 24 Mycobacterium avium subsp. 
paratuberculosis (MAP) recombinant proteins from 47 total proteins tested.   
Protein Description 
MAP 
Locus Tag 
Area Measurement 
(mm2) 
Standard 
Deviationa 
Acyl carrier protein 1997 231.52 87.70 
Elongation factor Tu 4143 209.08 124.13 
Electron transfer flavoprotein (Beta-subunit) 
FixA 
3061c 192.36 87.68 
Putative uncharacterized protein 2694 171.72 56.83 
Putative acyl-CoA dehydrogenase 3651c 166.53 77.51 
LprG protein 1138c 161.79 50.09 
Major membrane protein 1 2121c 128.90 11.11 
Peroxisomal multifunctional enzyme type 2 3567 121.26 N/A 
Chaperone protein DnaK 3840 110.91 N/A 
Putative uncharacterized protein 3692c 74.29 N/A 
Lipoprotein LprC 2497c 70.98 N/A 
Superoxide dismutase (Fragment) 0187c 65.95 N/A 
Fructose-bisphosphate aldolase class-I 4308c 61.16 N/A 
LppZ protein 3041 52.14 N/A 
DNA-binding protein HU 3024c 34.39 N/A 
Peptidyl-prolyl cis-trans isomerase 1693c 24.26 N/A 
Fatty acid desaturase 2698c 22.13 N/A 
Antigen 85-B 1609c 20.98 N/A 
ATP synthase subunit alpha 2453c 20.74 N/A 
Serine/threonine protein kinase 0016c 19.42 N/A 
Wag31 protein 1889c 18.36 N/A 
Putative uncharacterized protein 2020 14.79 N/A 
Peroxiredoxin 1589c 13.06 N/A 
6-phosphogluconolactonase 1174c 8.16 N/A 
Mbp/Lac-Z ---- 7.52 13.99 
PPD 9801 ---- 74.57 86.33 
PPD 0902 ---- 241.84 37.60 
Phosphate-Chloride Buffer (negative control) ---- 1.44 3.95 
a For the proteins which resulted in skin test responses for both inoculation sites the values represent the 
average response (mm2) and the standard deviation from two guinea pigs.  For the 17 proteins which 
exhibited only one positive skin test reaction the value represents the response from the single reactive 
inoculation and the standard deviation is not available (N/A). 
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Table 4:  Guinea pig potency testing of MAP recombinant proteins ranked by subtracted 
differences. 
MAP Protein 
(Locus tag) 
Rec 
Protein 
Mean 
MAP 
PPD 
9801 
Mean Differencea 
CI Upper 
Rangeb 
CI Lower 
Rangeb 
Guinea 
Pig ID’s 
MAP_1997 328.93 248.89 80.04 212.00 -51.93 
306, 312, 
318, 324, 
530 
MAP_4143 199.68 277.11 -77.43 0.83 -155.69 
304, 310, 
316, 322, 
528 
MAP_3567 192.05 272.39 -80.33 88.62 -249.28 
305, 311, 
317, 323, 
529 
MAP_1138c 173.70 264.41 -90.72 24.25 -205.68 
301, 307, 
313, 319, 
325 
MAP_3061c 106.80 277.11 -170.32 -73.52 -267.12 
304, 310, 
316, 322, 
528 
MAP_3651c 72.57 256.51 -183.94 -132.90 -234.99 
302, 308, 
314, 320, 
526 
MAP_2121c 74.40 272.39 -197.98 -63.20 -332.77 
305, 311, 
317, 323, 
529 
MAP_2497c 50.25 248.89 -198.65 -176.95 -220.34 
306, 312, 
318, 324, 
530 
MAP_3692c 34.73 243.82 -209.08 -141.21 -276.95 
303, 309, 
315, 321, 
527 
MAP_2694 42.20 256.51 -214.31 -133.99 -294.64 
302, 308, 
314, 320, 
526 
MAP_3840 47.95 264.41 -216.46 -92.78 -340.14 
301, 307, 
313, 319, 
325 
MAP_0187c 15.31 243.82 -228.51 -184.33 -272.68 
303, 309, 
315, 321, 
527 
 
aDifferences were calculated by subtracting the MAP protein skin test response from the PPD skin test 
response for each animal and then averaging the calculated differences for all animals in each treatment 
group. 
bUpper and lower range values represent 95% confidence interval (CI) calculations.    
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Figure 1:  Number of proteins identified by LC-MS/MS for each PPD preparation analyzed.  Proteins found 
in two or three PPD preparations are indicated by the black bars and proteins unique to each individual 
PPD preparation are indicated by the grey bars.  A total of 66 proteins were identified in PPD 0902A; 73 
proteins were identified in PPD 0902B; 110 proteins were identified in PPD 9801.  Ten proteins were 
identified as being in common within all three PPDs.  PPD 0902A contained 33 unique proteins, PPD 
0902B contained 45 unique proteins, PPD 9801 contained 77 unique proteins.  
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Figure 2:  Venn diagram illustrating protein overlaps between PPD 9801, PPD 0902A, and PPD 0902B.  
The number of proteins identified for each PPD is indicated.  Although the majority of proteins identified 
were unique to a given production lot, 10 proteins were present in all three lots analyzed (see Table S1). 
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Fig. 3  Guinea pig potency testing of 12 MAP recombinant proteins with average skin test reaction measurements (mm2) indicated.  
Asterisk label indicates significantly different skin test reactions compared to the MAP PPD 9801 reference. 
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Figure 4:  Secretion of IFN-γ using whole blood from Johne’s positive animals.  Absorbance was measured at 450 nm. 
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Figure 5:  Secretion of IFN-γ using whole blood from Mycobacterium bovis sensitized animals and negative animals.  Absorbance was measured at 450 nm.
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CHAPTER 5:  CONCLUSIONS 
 
 
General discussion 
Early detection of MAP-infected animals is a key strategy to controlling Johne’s 
disease in herds and improving overall herd management and production.  The use of 
PPDs for skin testing animals for Johne’s disease was the first diagnostic test used and 
other than moderate changes to the PPD production process there has been little 
advancement to improving this reagent.   
In 2005, the United States Animal Health Association passed a resolution seeking 
improvements to MAP PPD with a goal to develop a well characterized and consistent 
PPD.  This resolution, in combination with the USDA NVSL seeking to develop 
improved production techniques for various reagents, provided an opportunity to 
investigate more closely the PPD production process and characteristics of the PPDs 
produced at the NVSL. 
Diagnostic specificity issues have been well known for PPD used for Johne’s 
disease testing.  Before these issues can be addressed in current studies it is important to 
better understand the specific components of the PPD suspension.  The ability to evaluate 
protein banding patterns through electrophoretic processes is hindered because of the 
degradation of protein components during the autoclaving step of the PPD production 
process.  The ability to visualize protein banding patterns on a gel would offer a fairly 
rapid option for evaluating consistency between PPD production lots, but based upon 
current production protocols is not feasible. 
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This initial finding led to investigating modifications to develop an improved PPD 
production protocol as well as alternative processes for protein analysis.  Recent 
advances in defining the MAP genome allowed greater use of proteomic methodologies 
for protein analysis of PPDs.  Proteomic analysis of three PPDs provided an extensive list 
of proteins, but only a minor percentage were found to be present in all three 
preparations.   
Further work using the guinea pig potency test with a subset of the identified 
proteins provided additional data regarding which of the identified proteins may be good 
candidates for use in cell mediated immune response assays.  Data from the potency test 
evaluation indicates there are proteins that can be good candidates for further studies and 
investigations leading to production of a well characterized PPD that could be used in 
skin testing or IFN-γ assays. 
 
Development of an improved PPD production process 
Specific criteria for determining optimal incubation and harvest times for MAP 
cultures used for PPD production is lacking.  In the past, M. avium Strain 18 was used at 
the NVSL for MAP PPD production and was then replaced by MAP 19698.  This was a 
first step many years ago in improving MAP PPD.  Consistent harvest times of culture 
flasks may very well play a role in improving consistency between PPD production lots.  
An initial analysis of PPD produced by the traditional method revealed protein smearing 
on gels and an inability to clearly define protein banding patterns.   
Development of a modified production method involving sterile filtration rather 
than autoclaving with coarse filtration to inactivate and remove cells was investigated.  
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Degradation of proteins due to autoclaving during the traditional PPD production process 
resulted in difficulties discerning specific protein components through electrophoretic 
analysis.  PPD, produced through an alternative production method, evaluated on gels 
showed distinct banding patterns and allowed for better comparison of protein banding 
patterns between production lots. 
 
Proteomic evaluation of PPD 
Proteomic evaluation offers a powerful tool for in-depth information on specific 
protein composition of a PPD.  Results of proteomic evaluation of various NVSL PPDs 
has indicated inconsistency in protein expression, but has provided additional information 
of specific protein components.  There were 194 total proteins identified between three 
various PPDs, with 131 of those being MAP-related proteins.  These results were 
encouraging as being similar to other PPD suspensions that have been analyzed by mass 
spectrometry.  Increased emphasis has been occurring for use of proteomic evaluation of 
PPD products in an effort to aid in improved diagnostic tools related to cell mediated 
immune response detection. 
 
Potency evaluation of PPD and recombinant MAP proteins 
Potency testing of MAP PPDs that were produced either by use of sterile filtration 
or by autoclaving during the production process revealed significant differences between 
biological activity in sensitized guinea pigs.  These results indicate that the use of 
autoclaving during PPD production is not necessary and substituting sterile filtration in 
place of autoclaving may enhance antigenicity and prevent protein degradation.  More 
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important is ensuring the development of the alternative production process does not 
negatively affect potency.  The acceptable potency test results were an important finding 
should changes to the PPD production process be proposed in the future. 
Potency testing of individual recombinant MAP proteins provided data indicating 
that 24 proteins were responsive in MAP sensitized guinea pigs.  Seven of these proteins 
gave strong consistent reactions in the potency test and were individually equivalent to 
PPD.  This pool of identified proteins provides future consideration as a well-
characterized test reagent that can be reliably produced and have better quantitative 
parameters assigned for evaluation and release of a final product. 
 
Gamma-interferon testing using MAP recombinant proteins 
Use of selected MAP recombinant proteins as mitogens in the gamma-interferon 
assay showed that MAP_3651c and MAP_3567 had the greatest IFN-γ stimulation within 
the Johne’s positive cattle, and in some animals a greater response than resulting 
stimulation values from MAP PPD 9801.  Results also indicated variations of protein 
reactivity in the guinea pig potency test versus IFN-γ stimulation.  MAP_1997 provided 
the best skin test response in potency testing, but the least overall amount of IFN-γ 
stimulation from Johne’s positive animal blood samples.  This variation between 
responses in an in-vivo testing model and an in-vitro assay are important parameters to 
balance in selection of recombinant proteins holding the greatest promise for improved 
diagnostics.  Each MAP recombinant protein resulted in negative stimulation values from 
M. bovis sensitized animal samples as well as negative control animal samples.  These 
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results support the conclusion that good specificity was obtained using selected 
recombinant proteins for use in an in-vitro IFN-γ stimulation assay.  
 
Future research considerations 
Sensitivity and specificity of MAP PPD in tests to detect MAP infection in cattle 
is of primary importance.  Development of a well characterized PPD that can be used for 
both in-vivo and in-vitro testing will require evaluation in field tests comprising naturally 
infected animals from various regions and during varying climate conditions. 
The use of specific recombinant proteins should be further characterized by 
conducting skin testing in Johne’s positive cattle as well as further in-vitro validation 
using paired sampling and testing from animals included in a field study.  Identifying 
specific recombinant proteins that can offer strong stimulation characteristics in both skin 
tests and IFN-γ assays would allow for a well characterized suspension that could be used 
both in the field and laboratory. 
Ultimately, production of a well characterized PPD consisting of specific protein 
components at an established protein concentration for each protein would provide a 
much improved diagnostic reagent for use in skin testing and IFN-γ procedures.  This 
type of research would provide improved confidence in a MAP PPD and more rigorous 
test validation.    
 
 
 
 
